



Experimental Pathology Laboratories, Inc.

---

Ethyl-Tertiary-Butyl Ether  
C00117/00117-64

**PATHOLOGY QUALITY ASSESSMENT  
REVIEW AND PWG COORDINATOR'S REPORT  
FOR  
LIFETIME CARCINOGENICITY STUDY  
OF ETHYL-TERTIARY-BUTYL ETHER (ETBE)  
IN SPRAGUE-DAWLEY RATS**

**CONDUCTED AT**

**THE CANCER RESEARCH CENTER, EUROPEAN RAMAZZINI FOUNDATION  
FOR ONCOLOGY AND ENVIRONMENTAL SCIENCES, BOLOGNA, ITALY**

**CHEMICAL NO./TDMS NO.: C00117/00117-64**

Submitted to:

National Toxicology Program  
Research Triangle Park, NC 27709

Submitted by:

Experimental Pathology Laboratories, Inc.

Street Address:

615 Davis Drive  
Suite 500  
Durham, NC 27713

Mailing Address:

P.O. Box 12766  
RTP, NC 27709

(919) 998-9407

July 22, 2011

## Table of Contents

INTRODUCTION.....	2
EXPERIMENTAL DESIGN AND METHODS.....	2
RESULTS .....	4
Quality Assessment Review .....	5
Pathology Working Group Review .....	6
DISCUSSION.....	7
CONFLICT OF INTEREST STATEMENT .....	8
SIGNATURE PAGE .....	9
APPENDIX A	
Slide Review Work Sheets - Males .....	A-1
APPENDIX B	
Slide Review Work Sheets - Females .....	B-1
APPENDIX C	
PWG Participants Curricula Vitae .....	C-1



Experimental Pathology Laboratories, Inc.

---

Ethyl-Tertiary-Butyl Ether  
C00117/00117-64

### DISCLAIMER(S)

This document was produced to meet the requirements of Section 508 of the Rehabilitation Act. If you are unable to view or interpret these, please contact 919-998-9407 or [NTPQualityAssessment@epl-inc.com](mailto:NTPQualityAssessment@epl-inc.com). Some portions of this report may contain documents produced by third parties. These are provided for your convenience and may not meet the requirements of Section 508.



Experimental Pathology Laboratories, Inc.

---

## NARRATIVE

Ethyl-Tertiary-Butyl Ether  
C00117/00117-64

**PATHOLOGY QUALITY ASSESSMENT REVIEW AND  
PATHOLOGY WORKING GROUP (PWG) COORDINATOR'S REPORT  
FOR  
LIFETIME CARCINOGENICITY STUDY  
OF ETHYL-TERTIARY-BUTYL ETHER (ETBE)  
IN SPRAGUE-DAWLEY RATS**

**CONDUCTED AT**

**THE CANCER RESEARCH CENTER, EUROPEAN RAMAZZINI FOUNDATION  
FOR ONCOLOGY AND ENVIRONMENTAL SCIENCES, BOLOGNA, ITALY**

**CHEMICAL/TDMS NO.: C00117/00117-64**

Quality Assessment Review: February 7-18, 2011  
Date of the Pathology Working Group: April 4 – 8, 2011  
PWG Coordinator: Robert R. Maronpot, DVM, MPH  
Quality Assessment Pathologist: Kathleen A. Funk, DVM (EPL)  
Study Diagnoses: Ramazzini Institute  
PWG Participants:

Charles Clifford, DVM, PhD (Charles River)  
Sabine Francke-Carroll, DVM, PhD (FDA)  
Peter Greaves, MBChB (Leicester University)  
Jerry F. Hardisty, DVM (EPL)  
Peter C. Mann, DVM (EPL)  
James B. Nold, DVM, PhD (Biotechnics)

PWG Observers:

Steven Mog, DVM, PhD (FDA)  
Fiorella Belpoggi (Ramazzini Institute)  
Morando Soffritti, MD (Ramazzini Institute)  
Eva Tibaldi (Ramazzini Institute)  
Laura Falcioni (Ramazzini Institute)

## INTRODUCTION

This report by Experimental Pathology Laboratories, Inc. (EPL<sup>®</sup>) presents the results of the Quality Assessment Review and the Pathology Working Group (PWG) which reviewed glass slides subsequent to the Quality Assessment Review of the Ethyl-Tertiary-Butyl Ether (ETBE) study. The ETBE study was conducted by the Ramazzini Institute by gavage in extra virgin olive oil. The study started in 1993 and involved 360 rats.

## EXPERIMENTAL DESIGN AND METHODS

The numbers of animals used and their allocation to dose groups are shown in Table 1.

Table 1 – Study Design for Bioassay on Ethyl-Tertiary-Butyl Ether (ETBE) Administered in Drinking Water to Male and Female Sprague-Dawley Rats

Group	Dose (g/kg/day)	No. Rat and Sex
I	1	60 Males & 60 Females
II	0.25	60 Males & 60 Females
III	0 <sup>a</sup>	60 Males & 60 Females

<sup>a</sup>Olive Oil Alone

Results of study findings have been published previously by the Ramazzini Institute. The publication citations are as follows:

- Belpoggi, F., Soffritti, M., and Maltoni, C. (1999). Immunoblastic lymphomas in sprague-dawley rats following exposure to the gasoline oxygenated additives methyl-tertiary-butyl ether (MTBE) and ethyl-tertiary-butyl ether (ETBE): Early observations on their natural history. *Eur J Oncol* **4**, 563-572.
- Maltoni, C., Belpoggi, F., Soffritti, M., and Minardi, F. (1999). Comprehensive long-term experimental project of carcinogenicity bioassays on gasoline oxygenated additives: Plan and first report of results from the study on ethyl-tertiary butyl ether (ETBE). *Eur J Oncol* **4**, 493-508.

The peer review consisted of analysis of the Ramazzini Institute data and Quality Assessment (QA) of selected histopathology slides for the chronic lifetime study of ethyl-

tertiary-butyl ether (ETBE) in Sprague-Dawley rats. The EPA request was to conduct pathology peer review analysis of selected tumor types and preneoplastic and hyperplastic lesions in which the specific tumor type(s) was/were found increased by chemical treatment. The Quality Assessment Review of the pathology diagnoses was to include the examination of all sections of the oral cavity for hyperplastic and neoplastic changes from all male and female rats in all groups and all sections of the uterus and vagina for proliferative changes (hyperplasia, benign neoplasia and malignant neoplasms) for all female rats in all groups.

All slides with differences of opinion relating to the presence or absence of neoplasms in the tissues between the study and reviewing pathologist were identified for possible review by the Pathology Working Group.

Although all diagnoses reported by the Ramazzini pathologist were reviewed in each tissue, the focus of the technical approach was to achieve confirmation of proliferative lesions in the oral cavity, uterus, and vagina. The Quality Assessment (QA) review and included examination of the following:

- All sections of the oral cavity from all male and female rats in all groups for hyperplastic and neoplastic changes.
- All sections of uterus and vagina for hyperplastic and neoplastic lesions for all female rats in all groups.

Slide Review Work Sheets were used to document the results of the QA review. These work sheets list in animal number order tissues that were examined by the QA pathologist. In addition, these work sheets list the study pathologist's initial diagnosis for the tissues that were reviewed. The work sheets also record the QA pathologist's comments indicating agreement with the Ramazzini pathologist's diagnosis or a comment when a difference of opinion was noted.

The QA took place February 7 – 18, 2011 at the Ramazzini Institute. The number of slides examined during the QA review of the ETBE study is listed in Table 2.

Table 2. Number of Slides Reviewed During the QA Review

Group	Dose	Males	Females
		Slide Count	Slide Count
I	1.0 g/kg	305	471
II	0.25 g/kg	309	488
III	0 g/kg	304	442
	TOTAL	918	1401

The Pathology Working Group (PWG) met on April 6, 2011, and initially examined 36 slides from 12 rats across dose groups to determine the spectrum of proliferative changes in the oral cavity. These tissues were examined and the changes were discussed without voting on any diagnoses. The PWG Panel then examined a total of 139 slides from 80 rats in the ETBE study without knowledge of treatment group, sex (except for uterus & vagina slides), or previous diagnoses by the Ramazzini or QA pathologists. The PWG Panel examined representative slides from the following:

- All rats with a previous diagnosis of proliferative lesions including dysplasias, hyperplasias, and benign and malignant neoplasms affecting the oral mucosa and/or tongue.
- All proliferative, metaplastic, and neoplastic lesions in the uterus and vagina when there was a disagreement in diagnosis between the Ramazzini and QA pathologist.

The “Action to be Taken” column on the Slide Review Work Sheets is left blank because no post-PWG action was required.

## RESULTS

All materials necessary for this review were readily available and well organized. All slides required to be examined by the QA pathologist were present. The histologic quality of the sections was considered to be very good with no deficiencies that interfered with the examination of the tissues present or the interpretation of histopathologic changes that were present.



Quality Assessment Review

During the QA review, original terminology used for oral cavity lesions was noted by the QA pathologist to be made consistent with NTP nomenclature and practice. Specifically, Ramazzini diagnoses of dysplasia in the oral cavity were diagnosed by the QA pathologist as minimal squamous hyperplasia and Ramazzini diagnoses of proliferation in the oral cavity were diagnosed as minimal hyperplasia or considered within normal limits by the QA pathologist.

Slide Review Work Sheets used to document the results of the QA review are presented in Appendices A and B. These work sheets list in animal number order tissues that were examined by the QA pathologist from EPL. These work sheets list the initial diagnoses for the tissues which were reviewed and the QA pathologist's agreement or difference of opinion. The QA review consisted of oral cavity and tongue for identification of non-neoplastic and neoplastic proliferative lesions from all male and female rats in all groups. Uterus and vagina from all females in all groups were examined to document the presence of proliferative non-neoplastic and neoplastic lesions. When the QA pathologist had a difference of opinion with the initial diagnosis, an alternative diagnosis was listed on the Slide Review Work Sheets. All differences of opinion between the Ramazzini and QA pathologists for proliferative lesions in oral cavity, on tongue, or in uterus and vagina were selected for review by the PWG. The QA pathologist agreed with all study pathologist diagnoses of inflammation, atrophy, cysts, fibrosis, and ulceration in the oral cavity. Small areas of reactive hyperplasia of periodontal epithelium associated with inflammation were seen adjacent to broken teeth in some rats. Mixed inflammatory cell infiltrates present in the uterine and vaginal mucosa were confirmed by the QA pathologist.

Pathology Working Group Review

The primary focus during the PWG review was to distinguish between neoplastic and non-neoplastic proliferative lesions in the oral cavity, on the tongue, and in the uterus and vagina. Some ancillary lesions such as inflammation and atrophy were not specifically or formally voted on by the PWG Panel. Curricula vitae for the PWG participants can be found in Appendix C.

The PWG Panel reviewed 139 slides representing 80 rats. Panel members independently reviewed each slide and noted their findings and personal comments on work sheets. Following examination of a small number of specific tissues from 10 to 20 rats, the PWG Coordinator recorded consensus diagnoses for the relevant tissues for each rat. Occasional differences of opinion among the PWG Panel were discussed and; if a consensus diagnosis was not initially achieved, the relevant slides were re-examined by each Panel member followed by further discussion until a consensus diagnosis was achieved. The most significant lesions of concern for this ETBE study involved diagnosis of epithelial tumors in the oral cavity and epithelial and mesenchymal neoplasms in the uterus and vagina.

Diagnostic criteria for oral cavity and uterine/vaginal lesions used by the Pathology Working Group Panel followed internationally accepted guidelines (International Classification of Rodent Tumours. Part I: The Rat. 9. Female Genital System. IARC Scientific Publication No. 122. 1997; International Classification of Rodent Tumours. Part I: The Rat. 10. Digestive System. IARC Scientific Publication No. 122.1997; and Pathology of the Fischer Rat, Edited by Boorman et al., 1990. Academic Press, New York).

Oral cavity and uterine/vaginal lesion incidences are summarized in Tables 3 and 4, respectively.

Table 3: Incidence of Lesions in the Oral Mucosa/Tongue

MALES						
	0 g/kg/day		0.25 g/kg/day		1.0 g/kg/day	
No. of Rats per Group	60		60		60	
	SD	QA/PWG	SD	QA/PWG	SD	QA/PWG
Hyperplasia, Squamous	0	14	0	28	0	18
Papilloma	1	0	0	0	2	0
Squamous Cell Carcinoma	0	0	0	0	1	0
FEMALES						
	60		60		60	
No. of Rats per Group	SD	QA/PWG	SD	QA/PWG	SD	QA/PWG
Hyperplasia, Squamous	0	9	0	29	0	28
Papilloma	1	0	1	0	1	0
Squamous Cell Carcinoma	0	0	0	0	1	0

SD = Ramazzini Institute Study Diagnoses

QA/PWG = Combined QA/PWG Panel Consensus

Table 4: Proliferative Lesions in the Uterus/Vagina

	0 g/kg/day		0.25 g/kg/day		1.0 g/kg/day	
No. of Rats per Group	60		60		60	
	SD	QA/PWG	SD	QA/PWG	SD	QA/PWG
Metaplasia, Squamous	3	3	3	6	4	5
Stromal Polyp	21	21	11	12	14	14
Carcinoma	1	0	1	1	0	0
Leiomyoma	0	0	0	0	2	3
Leiomyosarcoma	1	1	2	0	0	0
Schwannoma, Malignant	0	0	6	7	2	2
Histiocytic Sarcoma	1	1	0	0	1	1

SD = Ramazzini Institute Study Diagnoses

QA/PWG = Combined QA/PWG Panel Consensus

## DISCUSSION

Oral cavity lesions documented in this study are typical age-related changes seen in chronic rat studies. The squamous hyperplasia was frequently in the oral cavity mucosa adjacent to teeth. Uterine stromal polyps and occasional mesenchymal tumors are common age-related changes seen in chronic rat studies. The incidence of malignant schwannomas in the 0.25 g/kg /day group is higher than what is usually seen.



#### CONFLICT OF INTEREST STATEMENT

This statement is to certify that the person listed below, employed by Experimental Pathology Laboratories, Inc., participated in the QA review and Pathology Working Group (PWG) from the Lifetime Carcinogenicity Study of Ethyl-Tertiary-Butyl Ether (ETBE) in Sprague-Dawley Rats conducted at the Cancer Research Center, European Ramazzini Foundation for Oncology and Environmental Sciences. He has not been involved in any aspect of the study for any organization other than NTP which conducted the study nor the generation and/or evaluation of materials or data which were reviewed prior to the receipt of materials from the study lab. Hence, his participation in the PWG poses no apparent or actual conflict of interest.

	
ROBERT R. MARONPOT, D.V.M., M.S., M.P.H. Diplomate, ACVP, ABT PWG Coordinator	DATE

RRM:asc



Experimental Pathology Laboratories, Inc.

---

**SIGNATURE PAGE**

## PATHOLOGY WORKING GROUP (PWG) PARTICIPANTS:




ROBERT R. MARONPOT, DVM, MS, MPH  
Diplomate, ACVP, ABT  
(PWG Coordinator)




PETER GREAVES, MBChB, FRC Path



SABINE FRANCKE-CARROLL, DVM, PhD, FIATP




CHARLES CLIFFORD, DVM, PhD  
Diplomate, ACVP



JAMES B. NOLD, DVM, PhD  
Diplomate, ACVP



PETER C. MANN, DVM  
Diplomate, ACVP



JERRY F. HARDISTY, DVM  
Diplomate, ACVP



Experimental Pathology Laboratories, Inc.

---

**APPENDIX A**  
**SLIDE REVIEW WORK SHEETS**  
**MALE**

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** MALE SD RATS

TMT 6

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1061	M121255	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	TISSUE NORMAL	
1062	M121265	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11)	TISSUE NORMAL	
1063	M121300	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1064	M121336	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1065	M121356	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1066	M122205	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1067	M122222	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9, 11)	NOT REVIEWED	
1068	M122258	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1069	M122282	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** MALE SD RATS

TMT 6

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1070	M122294	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1071	M121384	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1072	M121408	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1073	M121417	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10)[ADJACENT TO TOOTH]	NOT REVIEWED	
1074	M122140	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11)	NOT REVIEWED	
1075	M122165	5	ORAL MUCOSA - SQ CL PAPILLOM, PRESENT	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[WITH HYPERKERATOSIS]	TISSUE NORMAL	
1076	M123036	5	ORAL MUCOSA - ATROPHY, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 11)[WITH HYPERKERATOSIS]	NOT REVIEWED	
1077	M123047	5				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** MALE SD RATS

TMT 6

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1077	M123047	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1078	M123073	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1079	M123411	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1080	M123692	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1081	M120874	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1082	M120895	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	NOT PRESENT IN SECTION (8, 9, 11)	TISSUE NORMAL	
1083	M120924	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1084	M120948	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1085	M120958	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1086	M120973	5				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** MALE SD RATS

TMT 6

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1086	M120973	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1087	M120965	6	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10)	TISSUE NORMAL	
1088	M121008	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1089	M121036	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1090	M121046	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1091	M121062	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
1092	M121071	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1093	M121083	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
1094	M121097	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** MALE SD RATS

TMT 6

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1095	M121110	6	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1096	M121939	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1097	M121951	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1098	M121986	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1099	M120999	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1100	M122000	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10)[NEAR TOOTH]	NOT REVIEWED	
1101	M122026	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1102	M122041	7	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	TISSUE NORMAL	
1103	M122053	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** MALE SD RATS

TMT 6

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1104	M122065	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
1105	M122092	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1106	M122084	5	ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
1107	M122110	5	ORAL MUCOSA - ATROPHY, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)	NOT REVIEWED	
1108	M122115	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1109	M122903	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1110	M122914	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1111	M122928	5	ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** MALE SD RATS

TMT 6

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1111	M122928 Cont'd	5		ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
1112	M122940	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1113	M122971	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10)[ADJACENT TO TOOTH]	NOT REVIEWED	
1114	M122982	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1115	M122990	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1116	M123294	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10)[ADJACENT TO TEETH]	NOT REVIEWED	
1117	M123307	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10)[ADJACENT TO TOOTH]	NOT REVIEWED	
1118	M123314	5				

## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** MALE SD RATS

TMT 6

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1118	M123314	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1119	M123327	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1120	M123339	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
261	M121240	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
262	M121249	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
263	M121287	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
264	M121322	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 9, 11)[ADJACENT TO TOOTH SLIDE 10]	NOT REVIEWED	
265	M121345	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
			ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
266	M122178	5	ORAL MUCOSA - DYSPLASIA, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11)[ADJACENT TO TOOTH SLIDE 10]	NOT REVIEWED	
267	M122216	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
268	M122246	6	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
269	M122270	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
270	M122275	9	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (10, 11)	AGREE WITH REVIEWING PATHOLOGIST	
271	M121370	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
272	M121397	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
273	M121423	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
274	M121434	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	NOT PRESENT IN SECTION (9-11)	NOT REVIEWED	
275	M122153	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
276	M122305	5				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
276	M122305	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9-11)	TISSUE NORMAL	
277	M123029	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
278	M123063	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
279	M123085	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 9, 11)[ADACENT TO TEETH SLIDE 10]	NOT REVIEWED	
280	M123425	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9-11)	TISSUE NORMAL	
281	M123701	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 8-10)	NOT REVIEWED	
282	M120872	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)	AGREE WITH REVIEWING PATHOLOGIST	
283	M120893	9	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
284	M120922	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
285	M120946	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9-11)	TISSUE NORMAL	
286	M120956	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
287	M120971	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10)[ADJACENT TO TOOTH SLIDE 10]	NOT REVIEWED	
288	M120987	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	AGREE WITH REVIEWING PATHOLOGIST	
289	M121006	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 9-10)	NOT REVIEWED	
290	M121034	5	ORAL MUCOSA - LEUKEMIA MYELO, PRESENT	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
290	M121034 Cont'd	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9-11)	NOT REVIEWED	
291	M121044	6	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11)	NOT REVIEWED	
292	M121060	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9-11)	NOT REVIEWED	
293	M121089	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 9, 11)	NOT REVIEWED	
			ORAL MUCOSA - ULCER, MODERATE	AGREE	NOT REVIEWED	
294	M121103	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9-11)	NOT REVIEWED	
			ORAL MUCOSA - FIBROSIS, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
295	M121095	5				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
295	M121095	5	ORAL MUCOSA - DYSPLASIA, MILD	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9-11)	NOT REVIEWED	
			ORAL MUCOSA - ULCER, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA, BUCCAL - FIBROSIS, MODERATE	AGREE	NOT REVIEWED	
296	M121108	9	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[WITH HYPERKERATOSIS]	NOT REVIEWED	
			ORAL MUCOSA - FIBROSIS, MODERATE	AGREE	NOT REVIEWED	
297	M121937	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
298	M121967	5	ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[WITH HYPERKERATOSIS]	NOT REVIEWED	
299	M121984	5				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
299	M121984	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9-11)	NOT REVIEWED	
300	M120997	5	ORAL MUCOSA - CYST, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ULCER, MODERATE	AGREE	NOT REVIEWED	
				ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10)	NOT REVIEWED	
301	M122016	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 9, 11)	NOT REVIEWED	
302	M122024	5	ORAL MUCOSA - ULCER, MODERATE	AGREE	NOT REVIEWED	
				ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[WITH HYPERKERATOSIS]	NOT REVIEWED	
303	M122039	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
304	M122051	5				

## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
304	M122051	5	ORAL MUCOSA - LEUKEMIA MYELO, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 10)	NOT REVIEWED	
305	M122063	6	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 10)	TISSUE NORMAL	
			ORAL MUCOSA - FIBROSIS, MODERATE	AGREE[WITH HYPERKERATOSIS]	TISSUE NORMAL	
306	M122090	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 9, 11)[ADJACENT TO TOOTH]	TISSUE NORMAL	
307	M122082	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 9, 11)[ADJACENT TO TOOTH]	NOT REVIEWED	
308	M122108	5	ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
308	M122108 Cont'd	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9-11)	NOT REVIEWED	
309	M122131	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
310	M122901	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
311	M122912	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
312	M122946	0	ORAL MUCOSA - MISSING	AGREE	NOT REVIEWED	
313	M122958	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	NOT PRESENT IN SECTION (11)	TISSUE NORMAL	
314	M122969	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
315	M122980	4	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	NOT PRESENT IN SECTION (8- 10)[SLIDE 11 MISSING]	NOT REVIEWED	
316	M123003	5				



## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** MALE SD RATS

TMT 4

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
316	M123003	5	ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
				ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
317	M123292	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
318	M123305	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9-11)	TISSUE NORMAL	
319	M123312	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
320	M123355	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	

## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** MALE SD RATS

TMT 2

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
61	M121241	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
62	M121250	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
63	M121288	5	ORAL MUCOSA - DYSPLASIA, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
64	M121323	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
65	M121346	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
66	M122179	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
67	M122217	5	ORAL MUCOSA - DYSPLASIA, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 11)	NOT REVIEWED	
68	M122232	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
69	M122271	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 11)	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** MALE SD RATS

TMT 2

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
70	M122276	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
71	M121371	5	ORAL MUCOSA - PROLIFERATION, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 11)	TISSUE NORMAL	
72	M121398	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
73	M121424	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
74	M121435	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 11)	NOT REVIEWED	
75	M122104	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
76	M122306	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
77	M123030	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
78	M123064	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** MALE SD RATS

TMT 2

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
79	M123086	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
80	M123426	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9, 11)	TISSUE NORMAL	
81	M123702	6	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
82	M120873	6	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
83	M120894	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
84	M120923	5	ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
85	M120947	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
86	M120957	5	ORAL MUCOSA - DYSPLASIA, MARKED	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 11)	NOT REVIEWED	
87	M120972	6				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** MALE SD RATS

TMT 2

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
87	M120972	6	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11)	NOT REVIEWED	
88	M120988	5	ORAL MUCOSA - PROLIFERATION, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	TISSUE NORMAL	
89	M121007	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
90	M121035	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
91	M121045	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
92	M121061	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
93	M121070	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
94	M121082	5	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9-11)	TISSUE NORMAL	
95	M121096	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** MALE SD RATS

TMT 2

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
96	M121109	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
97	M121938	5	ORAL MUCOSA - PROLIFERATION, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11, 9)	NOT REVIEWED	
98	M121950	6	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	TISSUE NORMAL	
99	M121985	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
100	M120998	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
101	M121998	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
102	M122025	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11){HYPERKERATOSIS}	AGREE WITH REVIEWING PATHOLOGIST	
103	M122040	5	ORAL MUCOSA - PROLIFERATION, MODERATE	NOT PRESENT IN SECTION (9-11)	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** MALE SD RATS

TMT 2

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
104	M122052	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
105	M122064	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
106	M122091	6	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
107	M122083	5	ORAL MUCOSA - FIBROSIS, MODERATE	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - SQUAM CEL CARC, PRESENT	AGREE	ORAL MUCOSA: HYPERPLASIA, SQUAMOUS (10, 11)	
108	M122109	5	ORAL MUCOSA - PROLIFERATION, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 9-10)[WITH HYPERKERATOSIS]	AGREE WITH REVIEWING PATHOLOGIST	
109	M122114	5	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
110	M122902	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
111	M122913	5				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** MALE SD RATS

TMT 2

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
111	M122913	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
112	M122927	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
113	M122939	5	ORAL MUCOSA - PROLIFERATION, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
114	M122970	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11, 10)	AGREE WITH REVIEWING PATHOLOGIST	
115	M122981	5	ORAL MUCOSA - SQ CL PAPILLOM, PRESENT	AGREE	ORAL MUCOSA: HYPERPLASIA, SQUAMOUS (11)	
116	M123004	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
117	M123293	5	ORAL MUCOSA - PROLIFERATION, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 9, 11)[HYPERPLASIA WITH INFLAMMATION NEAR TOOTH SLIDE 10]	TISSUE NORMAL	
118	M123306	5				



## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** MALE SD RATS

TMT 2

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
118	M123306	5	ORAL MUCOSA - SQ CL PAPILLOM, PRESENT	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[WITH HYPERKERATOSIS]	TISSUE NORMAL	
119	M123313	5	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	AGREE WITH REVIEWING PATHOLOGIST	
120	M123326	5	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	



Experimental Pathology Laboratories, Inc.

---

**APPENDIX B**  
**SLIDE REVIEW WORK SHEETS**  
**FEMALE**

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1001	F121256	7	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
1002	F121274	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
1003	F121306	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1003	F121306 Cont'd	7	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9, 8, 10- 11)[PLANE OF SECTION SLIDE 9, 11]	TISSUE NORMAL	
1004	F121329	7	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1005	F121364	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1006	F122210	10	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - HISTIO SARC, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1006	F122210 Cont'd	10	UTERUS - LEIOMYOSAR, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - DYSPLASIA, MODERATE	NOT PRESENT IN SECTION (9, 8, 10-11)[PLANE OF SECTION SLIDE 11]	AGREE WITH REVIEWING PATHOLOGIST	
1007	F122238	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1008	F122262	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, MODERATE	NOT PRESENT IN SECTION (9, 8, 10-11)[PLANE OF SECTION SLIDE 11]	NOT REVIEWED	
1009	F122300	7				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1009	F122300	7	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1010	F123027	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1011	F121390	8	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1012	F121414	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1012	F121414 Cont'd	7	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[FOCAL WITH HYPERKERATOSIS]	TISSUE NORMAL	
1013	F122136	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1014	F122161	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[WITH HYPERKERATOSIS AND INFLAMMATION]	NOT REVIEWED	
1015	F122187	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1015	F122187 Cont'd	7	UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1016	F123059	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1017	F123081	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1018	F123419	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1018	F123419 Cont'd	8	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1019	F123698	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
1020	F120887	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1021	F120906	6	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1021	F120906 Cont'd	6	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1022	F120918	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11)[INFLAMMATION AND FOREIGN MATERIAL SLIDE 10, HYPERKERATOSIS SLIDE 11]	TISSUE NORMAL	
1023	F120935	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, MODERATE	NOT PRESENT IN SECTION (8-11)	AGREE WITH REVIEWING PATHOLOGIST	
			ORAL MUCOSA - SQ CL PAPILLOM, PRESENT	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MODERATE (11)	AGREE WITH REVIEWING PATHOLOGIST	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1024	F120949	8	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)[HYPERKERATOSIS]	NOT REVIEWED	
1025	F120976	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - CARCINOMA, PRESENT	NOT PRESENT IN SECTION (23)	TISSUE NORMAL	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1026	F120984	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1027	F121015	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1027	F121015 Cont'd	7	UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
1028	F121027	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1029	F121039	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
1030	F121057	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1030	F121057 Cont'd	8	UTERUS, ENDOMETRIUM - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (10-11)[INFLAMMATION SLIDE 10]	TISSUE NORMAL	
1031	F121077	7	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (10-11)[	NOT REVIEWED	
1032	F121093	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1033	F121934	7				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1033	F121934	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1034	F121956	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (10-11)[INFLAMMATION SLIDE 10, HYPERKERATOSIS SLIDE 11]	NOT REVIEWED	
1035	F121964	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1035	F121964 Cont'd	7	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1036	F121978	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (8- 11)[INFLAMMATION SLIDE 10-11]	NOT REVIEWED	
1037	F120992	7	VAGINA - NORMAL	NO SECTION PRESENT (22)	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1038	F121994	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1038	F121994 Cont'd	7	UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[]	NOT REVIEWED	
1039	F122008	6	VAGINA - NORMAL	MISSING SLIDE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1040	F122019	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - HYPERPLASIA, GLANDULAR, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
1041	F122036	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1041	F122036 Cont'd	7	UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1042	F122059	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	UTERUS - POLYP STROMAL (23)	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1043	F122079	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1044	F122098	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1044	F122098 Cont'd	8	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1045	F122121	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1046	F122896	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[]	AGREE WITH REVIEWING PATHOLOGIST	
1047	F122909	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1047	F122909 Cont'd	8	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1048	F122925	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1049	F122948	10	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1050	F122962	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1051	F122985	7				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1051	F122985	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1052	F122997	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
1053	F123007	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1054	F123296	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1054	F123296 Cont'd	8	UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1055	F123317	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1056	F123332	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (8-11)[WITH HYPERKERATOSIS, OVERLYING INFLAMED SALIVARY SLIDE 11]	TISSUE NORMAL	
1057	F123353	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1057	F123353 Cont'd	7	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MARKED	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11, 8- 10)[INFLAMMATION SLIDE 8 AND 10, HYPERKERATOSIS SLIDE 11]	NOT REVIEWED	
1058	F123375	8	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1059	F123390	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
1060	F123609	7	VAGINA - MISSING	AGREE	NOT REVIEWED	

## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** VEHICLE CONTROL  
**Sex & Species** FEMALE SD RATS

TMT 5

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** VEHICLE CONTROL  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1060	F123609 Cont'd	7	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
201	F121234	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
202	F121262	8	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, MODERATE	NOT PRESENT IN SECTION (9, 8, 10-11)[PLANE OF SECTION SLIDE 9-10]	NOT REVIEWED	
203	F121285	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9, 8, 10-11)[SLIDES BROKEN]	NOT REVIEWED	
204	F121317	14				



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
204	F121317	14	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - LEIOMYOSAR, PRESENT	UTERUS - SCHWANNOMA MALIGNANT (23)	AGREE WITH REVIEWING PATHOLOGIST	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
205	F121358	9	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8-11)[PLANE OF SECTION, HYPERKERATOSIS SLIDE 10-11]	NOT REVIEWED	
206	F122199	8	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MODERATE (11)[HYPERKERATOSIS SLIDE 11]	AGREE WITH REVIEWING PATHOLOGIST	
207	F122226	7				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
207	F122226	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8-11)[PLANE OF SECTION SLIDE 10-11]	NOT REVIEWED	
208	F122250	8	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
209	F122274	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - FIBROSIS, DIFFUSE, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
209	F122274 Cont'd	8	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8-11)[PLANE OF SECTION SLIDE 10-11]	NOT REVIEWED	
210	F123017	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - AMYLOID DEP, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MODERATE (11)[HYPERKERATOSIS SLIDE 11]	AGREE WITH REVIEWING PATHOLOGIST	
211	F121377	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
212	F121400	7				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
212	F121400	7	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
213	F121431	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 8-9, 11)[[]	TISSUE NORMAL	
214	F122150	7	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
214	F122150 Cont'd	7	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE  <Inserted Finding>	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)[]	NOT REVIEWED  TONGUE: HYPERPLASIA, SQUAMOUS (13, 13)	
215	F122175	8	VAGINA - NORMAL  UTERUS - NORMAL  ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	AGREE  AGREE  ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (10-11)[]	NOT REVIEWED  NOT REVIEWED  NOT REVIEWED	
216	F123053	7	VAGINA - NORMAL  UTERUS, CERVIX - INFLAMMATION, MODERATE  ORAL MUCOSA - DYSPLASIA, MODERATE	MISSING SLIDE  AGREE  ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MODERATE (11)[]	NOT REVIEWED  NOT REVIEWED  AGREE WITH REVIEWING PATHOLOGIST	
217	F123070	8	VAGINA - INFLAMMATION, MODERATE  UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE  AGREE	NOT REVIEWED  NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
217	F123070 Cont'd	8	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
218	F123406	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
219	F123687	9	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - DYSPLASIA, MODERATE	UTERUS - METAPLASIA, SQUAMOUS, MODERATE (23)	AGREE WITH REVIEWING PATHOLOGIST	
			UTERUS - INFLAMMATION, CHRONIC, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
220	F120871	12				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
220	F120871	12	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - SCHWANNOMA MAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8-11)[INFLAMMATION SLIDE 10]	TISSUE NORMAL	
221	F120900	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - FIBROSIS, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (8-11)[ON SLIDE 11]	NOT REVIEWED	
222	F120912	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
222	F120912 Cont'd	7	UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
223	F120920	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11, 8- 10)[OVERLYING INFLAMMATION SLIDE 11]	NOT REVIEWED	
224	F120937	10	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (9, 11)	NOT REVIEWED	
			ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
225	F120951	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
225	F120951 Cont'd	7	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 8- 10)[OVERLYING AREA OF INFLAMMATION SLIDE 11]	NOT REVIEWED	
226	F120978	7	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
227	F121002	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
228	F121017	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
228	F121017 Cont'd	8	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 8-9, 11)[HYPERPLASIA IN AREA OF INFLAMMATION AND FOREIGN MATERIAL SLIDE 10]	NOT REVIEWED	
229	F121029	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
230	F121051	13	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)[HYPERKERATOSIS SLIDE 11]	NOT REVIEWED	
			ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
231	F121065	8	VAGINA - NORMAL	NO SECTION PRESENT (22)	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
232	F121079	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	NOT PRESENT IN SECTION (23)	AGREE WITH REVIEWING PATHOLOGIST	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (9, 11, 8, 10)[OVERLYING AREA OF INFLAMMATION]	NOT REVIEWED	
233	F121105	13	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - SCHWANNOMA MAL, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11, 8-10)[HYPERKERATOSIS SLIDE 11]	NOT REVIEWED	
234	F121944	11				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
234	F121944	11	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - SCHWANNOMA MAL, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (10-11, 8-9)	NOT REVIEWED	
			<Inserted Finding>		TONGUE: NORMAL (13, 13)	
235	F121958	8	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
236	F121968	8	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
237	F121991	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
237	F121991 Cont'd	7	UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - SQ CL PAPILLOM, PRESENT	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)	TISSUE NORMAL	
238	F120994	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
239	F121996	6	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS - MISSING	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 8-10)	NOT REVIEWED	
240	F122010	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
240	F122010 Cont'd	7	UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11, 9-10)	NOT REVIEWED	
241	F122021	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11, 9-10)	NOT REVIEWED	
242	F122046	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - DYSPLASIA, SQUAMOUS, MODERATE	UTERUS - FIBROSIS, SQUAMOUS, MARKED (23)	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 9-10)	NOT REVIEWED	
243	F122061	11	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - LEIOMYOSAR, PRESENT	UTERUS - SCHWANNOMA MALIGNANT (23)	AGREE WITH REVIEWING PATHOLOGIST	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
243	F122061 Cont'd	11	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 9-10)	TISSUE NORMAL	
244	F122081	6	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MODERATE (10)	TISSUE NORMAL	
245	F122105	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
246	F122123	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
246	F122123 Cont'd	8	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MODERATE (11, 8-10)	AGREE WITH REVIEWING PATHOLOGIST	
247	F122898	9	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - CARCINOMA, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
				UTERUS - POLYP STROMAL (23)	AGREE WITH REVIEWING PATHOLOGIST	
			UTERUS - INFLAMMATION, MODERATE	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
248	F122911	12	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - SCHWANNOMA MAL, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 9- 10)[HYPERKERATOSIS SLIDE 11]	TISSUE NORMAL	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
249	F122964	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 8-10)	NOT REVIEWED	
250	F122950	8	VAGINA - SCHWANNOMA MAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS - SQUAM CEL CARC, PRESENT	UTERUS - METAPLASIA, SQUAMOUS, MODERATE (23)	AGREE WITH REVIEWING PATHOLOGIST	
			<Inserted Finding>		UTERUS: POLYP STROMAL (23)	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (8-11)	NOT REVIEWED	
251	F122973	9	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - HYPERPLASIA, GLANDULAR, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
251	F122973 Cont'd	9	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
252	F122987	8	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (9, 11)	TISSUE NORMAL	
			<Inserted Finding>		TONGUE: HYPERPLASIA, SQUAMOUS (11)	
253	F122999	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
253	F122999 Cont'd	8	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10, 8-9, 11)[INFLAMMATION SLIDE 10]	NOT REVIEWED	
254	F123009	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - INFLAMMATION, MODERATE	NOT PRESENT IN SECTION (8- 11)[UNREMARKABLE]	NOT REVIEWED	
255	F123298	9	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - DYSPLASIA, SQUAMOUS, MODERATE	UTERUS - CYST, SQUAMOUS (23)	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8)	NOT REVIEWED	
256	F123319	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
256	F123319 Cont'd	8	UTERUS - SCHWANNOMA MAL, PRESENT	AGREE	UTERUS: METAPL, SQUAMOUS (23)	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11, 10)[INFLAMMATION SLIDE 10]	NOT REVIEWED	
257	F123334	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (9, 11)[HYPERKERATOSIS SLIDE 11]	NOT REVIEWED	
258	F123355	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[WITH HYPERKERATOSIS]	NOT REVIEWED	
259	F123377	2	VAGINA - NORMAL	AGREE	NOT REVIEWED	

## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 0.25 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 3

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 0.25 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
259	F123377 Cont'd	2	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - MISSING	AGREE	NOT REVIEWED	
260	F123392	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 8-10)	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
1	F121223	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)	NOT REVIEWED	
2	F121261	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9, 11)	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8-11)	NOT REVIEWED	
3	F121284	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
4	F121316	8				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
4	F121316	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - LEIOMYOMA, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9-11)	TISSUE NORMAL	
5	F121349	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
6	F122198	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
6	F122198 Cont'd	7	ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
7	F122225	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9, 11)[HYPERKERATOSIS]	NOT REVIEWED	
8	F122249	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MILD	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	TISSUE NORMAL	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8-11)	AGREE WITH REVIEWING PATHOLOGIST	
9	F122273	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
9	F122273 Cont'd	7	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
10	F123016	7	VAGINA - MISSING	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
11	F121376	8	VAGINA - NORMAL	NOT PRESENT IN SECTION (22)	NOT REVIEWED	
			UTERUS - SCHWANNOMA MAL, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			<Inserted Finding>		UTERUS: POLYP STROMAL (23)	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11)	NOT REVIEWED	
12	F121399	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
12	F121399 Cont'd	7	ORAL MUCOSA - DYSPLASIA, MARKED	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 9-10)[PLANE OF SECTION SLIDE 11]	NOT REVIEWED	
13	F121430	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
14	F122149	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
14	F122149 Cont'd	8	ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
15	F122174	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - DYSPLASIA, SQUAMOUS, MODERATE	UTERUS, CERVIX - METAPLASIA, SQUAMOUS, MODERATE (23)	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
16	F123052	6	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, MODERATE	NOT PRESENT IN SECTION (8-11)	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, MODERATE	NOT PRESENT IN SECTION (8-11)	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
17	F123069	16	VAGINA - NORMAL	NOT PRESENT IN SECTION (22)	NOT REVIEWED	
			UTERUS - SCHWANNOMA MAL, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - ATROPHY, MARKED	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
18	F123405	8	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - DYSPLASIA, GLANDULAR, MODERATE	NOT PRESENT IN SECTION (23)	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
19	F123686	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - HISTIO SARC, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
20	F120870	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)[WITH HYPERKERATOSIS]	TISSUE NORMAL	
21	F120899	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
22	F120907	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - LEIOMYOMA, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	AGREE WITH STUDY PATHOLOGIST	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
23	F120919	9				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
23	F120919	9	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8-11)	TISSUE NORMAL	
24	F120936	9	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
25	F120950	8	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
25	F120950 Cont'd	8	ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
26	F120977	10	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - DYSPLASIA, SQUAMOUS, MODERATE	UTERUS - METAPLASIA, SQUAMOUS, MARKED (23)	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	TISSUE NORMAL	
27	F121001	11	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	

## SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
27	F121001 Cont'd	11	ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (8-11)	NOT REVIEWED	
28	F121016	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 8-10)	TISSUE NORMAL	
29	F121028	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (9, 11)	NOT REVIEWED	
30	F121040	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
30	F121040 Cont'd	7	ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
31	F121058	9	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - DEGEN, CYSTIC, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
32	F121078	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
33	F121104	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
33	F121104 Cont'd	8	ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (10-11)[WITH INFLAMMATION SLIDE 10]	NOT REVIEWED	
34	F121935	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (8-10)[WITH INFLAMMATION SLIDE 8-10]	NOT REVIEWED	
35	F121957	9	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[HYPERKERATOSIS]	NOT REVIEWED	
36	F121965	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
36	F121965 Cont'd	8	UTERUS - FIBROSIS, DIFFUSE, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
37	F121979	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (9, 11)	AGREE WITH REVIEWING PATHOLOGIST	
			ORAL MUCOSA - FIBROSIS, MODERATE	AGREE	AGREE WITH STUDY PATHOLOGIST	
			<Inserted Finding>		TONGUE: NORMAL (13)	
38	F120993	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (10-11)[WITH HYPERKERATOSIS]	NOT REVIEWED	
39	F121995	7				

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
39	F121995	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE[HYPERKERATOSIS SLIDE 11]	NOT REVIEWED	
			<Inserted Finding>		TONGUE: NORMAL (13)	
40	F122009	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
41	F122020	6	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
41	F122020 Cont'd	6	ORAL MUCOSA - SQ CL PAPILLOM, PRESENT	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)	TISSUE NORMAL	
42	F122045	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - FIBROSIS, DIFFUSE, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
43	F122060	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
				UTERUS - LEIOMYOMA (23)	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)[WITH HYPERKERATOSIS]	NOT REVIEWED	
44	F122080	14	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
44	F122080 Cont'd	14	UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - SQUAM CEL CARC, PRESENT	AGREE	ORAL MUCOSA: HYPERPLASIA, ATYPICAL (10, 11, 11R)	
45	F122104	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - HYPERPLASIA, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MINIMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)[HYPERKERATOSIS]	NOT REVIEWED	
46	F122122	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
47	F122897	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No. Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
47	F122897 Cont'd	7	UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
48	F122910	6	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - GRANULAR CELL TUMOR BENIGN (23)		NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
49	F122926	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
49	F122926 Cont'd	7	ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MARKED	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	AGREE WITH REVIEWING PATHOLOGIST	
50	F122949	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
51	F122972	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
52	F122986	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, CERVIX - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	



# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
52	F122986 Cont'd	7	UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11, 9- 10)[HYPERKERATOSIS SLIDE 11]	NOT REVIEWED	
53	F122998	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
54	F123008	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)	NOT REVIEWED	
55	F123297	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
55	F123297 Cont'd	8	UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
56	F123318	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - NORMAL	AGREE	NOT REVIEWED	
			ORAL MUCOSA - NORMAL	AGREE	NOT REVIEWED	
57	F123333	7	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MINIMAL (11)	NOT REVIEWED	
58	F123354	8	VAGINA - NORMAL	AGREE	NOT REVIEWED	
			UTERUS - METAPL, SQUAMOUS, MODERATE	AGREE	NOT REVIEWED	

# SLIDE REVIEW WORKSHEET

**Study Title** ETHYL-TERT-BUTYL-ETHER (ETBE)  
**Laboratory** CRC  
**Group** 1.0 G/KG  
**Sex & Species** FEMALE SD RATS

TMT 1

**Chemical #** C00117/00117-64  
**CAS #** 637-92-3  
**Dosage** 1.0 G/KG  
**Sacrifice** CHRONIC

CID Number	Histology Number	No Of Slides	Study Pathologist's Diagnoses	Reviewing Pathologist's Comments	PWG Coordinator's Comments PWG Consensus	Action To Be Taken <i>blank = No Change Required</i>
58	F123354 Cont'd	8	ORAL MUCOSA - ATROPHY, MODERATE	AGREE	NOT REVIEWED	
59	F123376	7	VAGINA - NORMAL	NOT PRESENT IN SECTION (22)	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - DYSPLASIA, SQUAMOUS, MODERATE	ORAL MUCOSA - HYPERPLASIA, SQUAMOUS, MILD (11)[HYPERKERATOSIS]	TISSUE NORMAL	
60	F123391	7	VAGINA - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			UTERUS - POLYP STROMAL, PRESENT	AGREE	NOT REVIEWED	
			UTERUS, ENDOMETRIUM - INFLAMMATION, MODERATE	AGREE	NOT REVIEWED	
			ORAL MUCOSA - PROLIFERATION, DIFFUSE, MODERATE	NOT PRESENT IN SECTION (9-11)	TISSUE NORMAL	



Experimental Pathology Laboratories, Inc.

---

## **APPENDIX C**

### **PWG PARTICIPANTS CURRICULA VITAE**

**Charles B. Clifford, D.V.M., Ph.D.**

email charles.clifford@crl.com

**Present Position**

Director, Pathology and Technical Services, Charles River

**Education**

1974	B.S. (Zoology)	Michigan State University
1977	D.V.M.	Michigan State University
1981-1983	Pathology Residency	Walter Reed Army Institute of Research
1988	Ph.D. (Pathology) minors in Immunology and Cell Biology	Cornell University

**Professional and Scientific Societies**

American College of Veterinary Pathologists (Diplomate, by examination)	1983 - present
Society of Toxicologic Pathologists (Full Member)	1989 - present
American Veterinary Medical Association	1981 - present
American Association of Laboratory Animal Science	1992 - present

## Experience

- 1977-1978 Veterinary Officer, Veterinary Detachment, Bayonne, NJ. Supervised approximately 30 civilian and military personnel who inspected most subsistence shipped to the U.S. military in Europe. Conducted sanitary inspection of 5 commissaries and over 80 civilian food processors and suppliers in New York City, Long Island and northern New Jersey. Responsible for zoonosis control at 4 Army posts.
- 1978 Assistant Officer-in-Charge, Team D, 106th Medical Detachment, Pusan, Republic of Korea. Supervised inspection of all subsistence shipped to the U.S. Army in Korea, and managed the only two military veterinary clinics within a 90 mile radius.
- 1978-1979 Officer-in-Charge, Team A, 106th Medical Detachment, Oujongbu, Republic of Korea. Supervised all food inspection for U.S. troops stationed north of Seoul, including along the DMZ, public health consultation for the 2nd Infantry Division. Also was Assistant Chief and Surgeon for the U.S. Army veterinary clinic in Seoul.
- 1979-1980 Course Director, US Army Animal Care Specialist School, Washington, DC, the only school in the U.S. Army to train Animal Health Technicians. Was responsible for course content and administration, counseling and supervision of 5 faculty members, and 120 students per year. Taught courses in pathology, anesthesia, radiology, and the Cardiovascular, Respiratory and Gastrointestinal System.
- 1980-1983 Pathology Resident, Division of Pathology, Walter Reed Army Institute of Research. Provided collaborative histopathology support to the institute, including studies of renal toxicity, pulmonary trauma and toxicity using rodent, lagomorph, canine, and primate models. Served as diagnostic pathologist for the Institute's rodent and primate colonies. Completed all requirements for the board examination of the American College of Veterinary Pathologists.
- 1982-1984 Assistant Senior Army Social Aide to the President of the United States for White House functions, such as receptions and State dinners.
- 1983-1984 Staff Pathologist, Division of Pathology, Walter Reed Army Institute of Research. Developed a rat model and conducted independent research on pathogenesis and healing of pulmonary lesions due to concussive pressure waves. Collaborated in studies of hemorrhagic shock, military systems hazards assessment, and toxicopathology of anti-schistosomal drugs. Assisted in training of 3 pathology residents per year in preparation of the veterinary pathology board examination.
- 1984-1987 Research Assistant (doctoral student), Cornell University. Conducted original research on the ontogeny of neutrophil function and the inflammatory response, comparing fetuses, neonates, and adults. Designed a novel model of *in utero* pulmonary inflammation in the sheep, permitting repetitive blood sampling and bronchoalveolar lavage. Initiated and developed a histopathology training series for

3 veterinary pathology residents from non-English speaking countries. Each resident then successfully completed the veterinary pathology board examination. Completed all requirements for Doctor of Philosophy degree.

- 1987-1991 Research Pathologist and Assistant Chief of Pathology, Letterman Army Institute of Research. Supervised the Institute's postmortem and clinical pathology laboratories. Conducted original research in distribution and toxicity of purified modified hemoglobin solutions. Collaborated with other scientists in model design and pathology support of Good Laboratory Practices Act-compliant toxicity studies (principal pathologist), pathogenesis of neurovascular trauma, hemorrhagic shock and perfusion injury, wound healing, and pre-clinical testing of candidate resuscitative fluids. Served on a rotating duty as diagnostic pathologist for animal postmortem examinations. Member of the Institute's Animal Care and Use Committee.
- 1991-2001 Staff Officer, US Army Medical Research and Materiel Command. Two weeks annual duty as a senior staff member in office with budget and program oversight of all Army biomedical research concerning biological and chemical agents, >\$100 million/annum. Duties included technical review of research proposals, analysis and synopsis of diverse research projects for senior pentagon management. Retired as Colonel.
- 1991-1993 Senior Pathologist, Charles River Laboratories. Oversee all aspects of pathology support of the world's largest supplier of laboratory animals, with approximately \$600 million in annual sales and production facilities in the U.S. and more than 10 other countries. Collaborate in the definition of new animal models, including genetically engineered animals. Supervise extramural development of new diagnostic technologies. Design and conduct pathology service protocols in support of biotechnology and pharmaceutical customers. Address and resolve customer concerns regarding unexpected research findings or other pathology-related issues. Key professional for CRL swine xenotransplantation efforts.
- 1993-present Director, Pathology and Technical Services. (*additional duties to above*) Supervise two other pathologists and the Charles River Technical Assistance Department, which provides information to customers concerning normative data, test procedures, husbandry, health, and all other matters relating to laboratory animals. Oversee corporate toxicology consultant, preparation of technical and reference papers on Historical Control Data..
- 2001-2003 (additional duties) Direct responsibility for Contract Research Services department, approximately \$2 million annual revenue. Specialty areas include oncology, vaccine testing, novel imaging studies.

## **Licensure**

Michigan, #5124, 1977 to present.

## **Inventions**

Hairless Immunodeficient Mouse Model (U.S. application no. 12/047,948)

## **PUBLICATIONS**

1. **Clifford, C.B.**, Jaeger, J.J., Moe J.B., and Hess, J.L., Gastrointestinal Lesions in Lambs Due to Multiple Low-Level Blast Over-Pressure Exposure. *Military Medicine*, 149:491-495, 1984.
2. Zwahlen, R.D., Slauson, D.O., Neilsen, N.R., and **Clifford, C.B.**, Increased Adhesiveness of Complement-Stimulated Calf Neutrophils and Its Pharmacologic Inhibition. *Journal of Leukocyte Biology*, 41:465-473, 1987.
3. Boswell, G.D., Brooks, D.E., Murray, A.J., Doye, A.A., Disselhorst, D.J. Chin, C.L., and **Clifford, C.B.**, Exogenous Methemoglobin as a Cyanide Antidote in Rats. *Pharmaceutical Research*, 5:749-752, 1988.
4. **Clifford, C.B.**, Slauson, D.O., Neilsen, N.R., Suyemoto, M.M., Zwahlen, R.D., and Schlafer, D.H., Ontogeny of Inflammatory Responsiveness: Superoxide Anion Generation by Phorbol Ester-Stimulated Fetal, Neonatal, and Adult Bovine Neutrophils. *Inflammation*, 13:221-231, 1989.
5. **Clifford, C.B.**, Wessels, D.W., and Smith, C.D., Morphologic effects of hypervolemic administration DBBF hemoglobin in the rat, *Biomaterials, Art. Cells, Art. Organs*, 18:321-328, 1990.
6. Schuschereba, S.T., **Clifford, C.B.**, Vargas, J.A., Bunch, D., and Bowman, P.D., Morphologic alteration in rat retina after hypervolemic infusion of cross-linked hemoglobin, *Biomaterials, Art. Cells, Art. Organs*, 18:299-307, 1990.
7. Sondeen, J.L., Gonzaludo, G.A., Loveday, J.A., Deshon, G.E., **Clifford, C.B.**, Hunt, M.M., Rodkey, W.G., and Wade, C.E., Renal Responses to Graded Hemorrhage in Conscious Pigs. *Am J Physiol*, 259:R119-R125, 1990.
8. Yuan, X-Q, Wade C.E., and **Clifford, C.B.**, Traumatic Brain Injury Suppresses Spontaneous Hemodynamic Recover from Hemorrhagic Shock in Rats, *J. Neurosurg.* 75:408-414, 1991.



9. Yuan, X-Q, Wade C.E., and **Clifford, C.B.**, Immediate hypertensive response to fluid percussion brain injury may be related to intracerebral hemorrhage and hypothalamic damage. *J.Neurotrauma*, 8:219-228, 1991.
10. Dubick, M.A., Pfeiffer, J.W., **Clifford, C.B.**, Runyon, D.E., Kramer, G.C., Comparison of Intraosseous and Intravenous Delivery of Hypertonic Saline/Dextran in Anesthetized, Euvolemic Pigs, *Annals of Emergency Medicine*, 21:498-503, 1992.
11. Pascual, J.M.S., Runyon, D.E., Watson, J.C., **Clifford, C.B.**, Dubick, M.A., Kramer, G.C., Resuscitation of hypovolemia in pigs using near saturated sodium chloride solution in dextran, *Circulatory Shock*, 40:115-124, 1993.
12. Runyon, D., Bruttig, S, Dubick, M., **Clifford, C.**, Kramer, G., Resuscitation from hypovolemia in swine with intraosseous infusion of a saturated salt-dextran solution, *Journal of Trauma* 36:11-19, 1994.
13. **Clifford, C.B.**, Walton, B.J., Reed, T.H., Coyle, M.B., White, W.J., and Amyx, H.L., Hyperkeratosis in nude mice caused by a coryneform bacterium: Microbiology, transmission, clinical signs, and pathology, *Laboratory Animal Science*, 45:131-139, 1995.
14. Moore, D.H., **Clifford, C.B.**, Crawford, I.T., Cole, G.M., and Baggett, J.M., Review of nerve agent inhibitors and reactivators of acetylcholinesterase, in Enzymes of the Cholinesterase Family, edited by Quinn, D.M., *et al.*, pp. 297-304, Plenum Press, New York 1995.
15. **Clifford CB**, Samples, sample selection, and statistics: living with uncertainty. *Lab Anim (NY)* (2001 Nov) 30(10):26-31
16. Vargas, K.J., Stephens, C., **Clifford, C.B.**, Gray, K.N., and Price, R.E. Dystrophic cardiac calcinosis in C3H/HeN mice. *Laboratory Animal Science*, 46:572-575, 1996.
17. Loeb, W.F., Das, S.R., Harbour, L.S., Turturro, A., Bucci, T.J., and **Clifford, C.B.**, Clinical biochemistry, in Pathobiology of the Aging Mouse, Vol. 1, edited by Mohr, U., *et al.*, pp. 3-20, ILSI Press, Washington, D.C., 1996
18. Evans, M.G., Cartwright, M.E., Sahota, P.S., and **Clifford, C.B.**, Proliferative lesions of the skin and adnexa in rats. In: **Guides for Toxicologic Pathology**. STP/ARP/AFIP, Washington DC., 1997
19. **Clifford, C.B.**, and White, W.J., The guinea pig, in The Clinical Chemistry of Laboratory Animals, 2<sup>nd</sup> edition, edited by Loeb, W.F. and Quimby, F.W., pp.65-70, Taylor & Francis, Philadelphia, P.A., 1999.
20. Gaillard, E.T., and **Clifford, C.B.**, Common Diseases, in The Laboratory Rat, edited by Krinke, G.J., pp. 99-132, Academic Press, San Diego, 2000.

21. Crippa,L.; Gobbi,A.; Ceruti,R.M.; **Clifford,C.B.**; Remuzzi,A.; Scanziani,E. Ringtail in suckling Munich Wistar Fromter rats: A histopathologic study. *Comparative Medicine* 50(5):536-539, 2000.
22. **Clifford CB**, Samples, sample selection, and statistics: living with uncertainty. *Lab Anim* (NY) 30(10):26-31, 2001
23. Kohn, D.F., and **Clifford, C.B.**, Biology and Diseases of Rats, in Laboratory Animal Medicine, edited by Fox, J.G., et. al., Academic Press, San Diego, 2002
24. Bemis, D.B., Shek, W.R., and **Clifford, C.B.**, *Bordetella bronchiseptica* infection of Rats and Mice. *Comparative Medicine*, 53(1):11-20, 2003
25. Shek WR, Pritchett KR, **Clifford CB**, White WJ, Large-scale rodent production methods make vendor barrier rooms unlikely to have persistent low-prevalence parvoviral infections. *Contemp Top Lab Anim Sci* 44(4):37-42, 2005
26. Rohde CM, Wells DF, Robosky LC, Manning ML, **Clifford CB**, Reily MD, Robertson DG Metabonomic evaluation of Schaedler altered microflora rats. *Chem Res Toxicol* 20(10):1388-92, 2007
27. **Clifford, CB**, and Watson, J. Old enemies, still with us after all these years. *ILAR Journal*, 49(3):291-302, 2008
28. Pritchett-Corning, KR, Cosentino, J, and **Clifford, CB**, Prevalence of infectious agents in laboratory mice and rats, *Laboratory Animals*, 43:165–173, 2009
29. Albers, TM, Simon, MA and **Clifford, CB**, Histopathology of Naturally Transmitted "Rat Respiratory Virus": Progression of Lesions and Proposed Diagnostic Criteria, *Veterinary Pathology*, 46:992-999, 2009.
30. **Clifford, C.B.**, and Simmons, J., The Hamster, in The Clinical Chemistry of Laboratory Animals, 3<sup>rd</sup> edition, edited by Kurtz, D.M., Prescott, J.S., and Travlos, G., Taylor & Francis, Philadelphia, P.A., *In Press*.
31. Schaffer BS, Grayson MH, Wortham JM, Kubicek CB, McCleish AT, Prajapati SI, Nelon LD, Brady MM, Jung I, Hosoyama T, Sarro LM, Hanes MA, Rubin BP, Michalek JE, **Clifford CB**, Infante AJ, Keller C, Immune competency of a hairless mouse strain for improved preclinical studies in genetically engineered mice. *Mol Cancer Ther* (2010 Aug) 9(8):2354-64

## TECHNICAL REPORTS

1. Frost, D.F., Hall, R.D., Zaucha, G.M., Waring, P.P., **Clifford, C.B.**, Wheeler, C.R. and Korte, D.W., Twenty-eight Day Subchronic Toxicity Study of Physostigmine Salicylate in Beagle Dogs. Institute Report #310, Letterman Army Institute of Research, U.S. Army, October 1988.
2. Frost, D.F., Omaye, S.T., Zaucha, G.M., **Clifford, C.B.**, Wheeler, C.R., Schuschereba, S.T., and Korte, D.W., Twenty-eight Day Subcutaneous Subchronic Toxicity Study of Physostigmine Salicylate in Rats. Institute Report #317, Letterman Army Institute of Research, U.S. Army, November 1988.
3. Frost, D.M., Zaucha, G.M., Omaye, S.T., **Clifford, C.B.**, and Korte, D.W., Acute Intravenous Toxicity of Hypertonic Saline/Dextran 70 and its Constituents in Beagle Dogs. Institute Report #392, June 1989.
4. Zaucha, G.M., Frost, D.F., Omaye, S.T., **Clifford, C.B.**, and Korte, D.W., Fourteen-Day Subacute Intravenous Toxicity Study of Hypertonic Saline/Dextran 70 and its Constituents in Beagle Dogs. Institute Report #404, Letterman Army Institute of Research, November 1989.
5. Magnuson, D.K., Zaucha, G.M., **Clifford, C.B.**, and Korte, D.W., Primary Dermal Irritation of Physostigmine Salicylate, Physostigmine Free-Base, and Pyridostigmine Bromide in New Zealand White Rabbits. Institute Report #438, Letterman Army Institute of Research, January 1990.
6. Coppes, V.G., Gomez, C.L., **Clifford, C.B.**, Ferraris, S., and Korte, D.W., Toxic Potential of Nitroguanidine on Reproduction and Fertility in Rats, Institute Report #434, Letterman Army Institute of Research, May 1990.
7. Morgan, E.W., Zaucha, G.M., Waring, P.P., LeTellier, Y., Seewald, J.B., **Clifford, C.B.**, and Korte, D.W., Ninety Day Subchronic Oral Toxicity Study of Pyridostigmine Bromide in Rats. Institute Report #435, Letterman Army Institute of Research, May 1990.
8. Morgan, E.W., Zaucha, G.M., Waring, P.P., LeTellier, Y., Seewald, J.B., **Clifford, C.B.**, and Korte, D.W., One Hundred Eighty Day Subchronic Oral Toxicity Study of Pyridostigmine Bromide in Rats. Institute Report #441, Letterman Army Institute of Research, June 1990.

## ABSTRACTS

1. Slauson, D.O., Skrabalak, D.S., Zwahlen, R.D., Neilsen, N.R. and **Clifford, C.B.**, Equine Neutrophil Aggregation and Adhesiveness Responses to C5a and AGEPC. Joint Conference of the International Leukocyte Culture conference and the Reticuloendothelial Society, 1985.
2. Zwahlen, R.D., Slauson, D.O., Neilsen, N.R., and **Clifford, C.B.**, Adhesiveness Responses of Neonatal Neutrophils to Zymosan-Activated Plasma. Joint Conference of the International Leukocyte Culture Conference and the Reticuloendothelia Society, 1985.
3. **Clifford, C.B.**, Slauson, D.O., Zwahlen, R.D., Schlafer, D.H., and Neilsen, N.R., Superoxide Anion Generation by Bovine Neutrophils: A Comparison of Fetal, Neonatal, and Adult Cells. American College of Veterinary Pathologists Annual Meeting, December, 1985.
4. Zwahlen, R.D., Slauson, D.O., Neilsen, N.R., and **Clifford, C.B.**, Adhesiveness of C5a-Treated Bovine Neonatal Neutrophils: Influence of Anti-Inflammatory Agents. American College of Veterinary Pathologists Annual Meeting, December 1985.
5. Slauson, D.O., Zwahlen, R.D., Neilsen, N.R., and **Clifford, C.B.**, Aggregation and Adhesiveness Responses of Equine Neutrophils to C5a and Platelet Activating Factor. American College of Veterinary Pathologists Annual Meeting, December 1985.
6. Slauson, D.O., Zwahlen, R.D., Neilsen, N.R., **Clifford, C.B.**, Bochsler, P.N., and Enright, F.M., Pharmacologic Inhibition of C5a-induced Increased Adhesiveness of Newborn and Adult Neutrophils by Steroidal and Non-Steroidal Anti-Inflammatory Drugs. American College of Veterinary Pathologists Annual Meeting, December 1986.
7. Miller, R.E., Lightner, L., **Clifford, C.B.**, Reid, W.A., Jones, D., and Witter, K.R., The Efficacy of Topically Applied Niclosamide at Preventing Schistomiasis mansonii in Rhesus Monkeys. American Society of Tropical Medicine and Health Annual Meeting, 1988.
8. Loveday, J.A., Gonzaludo, G.A., Sondeen, J.L., Rodkey, W.G., **Clifford, C.B.**, Deshon, G.E., Wade, C.E., Surgical Preparation for the Study of Renal Function in Conscious Swine. Presented at American Association for Laboratory Animal Science Annual Meeting, 1989.
9. **Clifford, C.B.**, Wessels, D.W., and Smith, C.D., Morphologic Effects of HBXLA99 in Rats, Biomaterials, Art. Cells, Art. Organs, 17:680, 1989.
10. Schuschereba, S.T., **Clifford, C.B.**, and Vargas, J.A., Effects of Hypervolemic Infusion of Cross-Linked Hemoglobin (DBBF-Hb) on the Rat Retina, Biomaterials, Art. Cells, Art Organs, 17:698, 1989.

11. Korte, D.W., Frost, D.F., Zaucha, G.M., Waring, P.P., **Clifford, C.B.**, and Wheeler, C.R., 28-day Toxicity in Beagle Dogs of Physostigmine Salicylate Administered via Subcutaneously Implanted Alzet Osmotic Minipumps, *Proc. West. Pharmacol. Soc.*, 32:159, 1989.
12. Dubick, M.A., Runyon, D.E., **Clifford, C.B.**, and Kramer, G.C., Comparison of Intraosseous with IV Infusions of Hypertonic Saline Dextran-70, *Ann. Emerg. Med.*, 20:480, 1991.
13. Runyon, D.E., **Clifford, C.B.**, Bruttig, S.P., Wade, C.E., Dubick, M.A., and Kramer, G.C., Resuscitation of Hypovolemia Using Intraosseous Infusion of a Small Volume of 25% NaCl/24% Dextran-70, *Ann. Emerg. Med.*, 20:480, 1991.
14. Bowman, P.D., **Clifford, C.B.**, McFaul, S.J., Tacha, D., and Johnson, T.W., Distribution of Purified Hemoglobin in Mouse Tissue as a Function of Time after Administration: An Immunocytochemical Study. *FASEB*, 1991.
15. **Clifford, C.B.**, Gianni, F.J., and White, W.J., *Pneumocystis carinii* and modern methods of rodent breeding and husbandry. Joint meeting of Am Soc Parasitologists and Soc Protozoologists, 1996.
16. Henderson, K.S., **Clifford, C.B.**, and Dionne, J.A., Comparison of the polymerase chain reaction with histological technique for detection of *Pneumocystis carinii*. Joint meeting of Am Soc Parasitologists and Soc Protozoologists, 1996.
17. Kim, N.M., Bailey, L., Olson, T., **Clifford, C.B.**, Benso, F.J., Sgrulloni, S.J., Duenas, E., Cleland, J.L., Putney, S.D., and Riley, M.G.I., Immunogenicity evaluation of ProLease® hGH: A sustained release formulation. Society of Toxicology, 1997.
18. Albers, T.M. and **Clifford, C.B.** Eosinophilic granulomatous pneumonia: A strain-related lesion of high prevalence in the Brown Norway rat, *Contemporary Topics*, 39(4):61-62, 2000
19. Albers, T. M. and **Clifford, C. B.** Transmission of rat respiratory virus in a rat colony: Gross and histopathological progression of lesions. *Contemp Top.Lab Anim Sci* 42[4], 73-74. 2003.

Curriculum Vitae  
**Dr. Sabine FRANCKE-CARROLL**  
Veterinary Medical Officer / Expert Toxicologic Veterinary Regulatory Review Pathologist

DHHS/CFSAN/FDA/ OFAS/ Senior Science and Policy Staff /Pathology  
5100 Paint Branch Parkway HFS-205  
College Park MD 20740  
(301) 436-1308

**EDUCATION:**

Ph.D., The Ohio State University, Columbus, OH, USA  
Applied Veterinary Pathology Residency, The Ohio State University, Columbus, OH, USA  
Dr. Vet. Med., Justus-Liebig University, Giessen, Germany  
D.V.M., Justus-Liebig University, Giessen, Germany

**PROFESSIONAL ORGANIZATIONS AND MEMBERSHIPS:**

Recognized Fellow of the International Academy of Toxicologic Pathology (IATP; 2010 - present)  
European Society of Toxicologic Pathology (ESTP; 2009 – present)  
US Society of Toxicologic Pathology (STP; 1998 - present)  
American College of Toxicology (ACT; 1999 - present)  
Association of Government Toxicologists (AGT; 2000- present) – President Elect (2009-11)  
Charles Louis Davis D.V.M. Foundation for the Advancement of Veterinary and Comparative Pathology (2000 – present)

United States and Canadian Academy of Pathology, Inc. (USCAP 2000-2010)  
American Association for the Advancement of Science (AAAS 1992-2010)  
National Society for Histotechnology (NSH 2004-2009)

**PROFESSIONAL EXPERIENCE:**

**CURRENT DUTIES:**

Expert Toxicologic Veterinary Regulatory Review Pathologist, Senior Science and Policy Staff / Pathology  
Department of Health and Human Services / FDA / CFSAN / OFAS /College Park, MD.  
4/10 – present

The incumbent in the Office of Food Additive Safety (OFAS) in CFSAN is recognized by FDA as subject matter expert for Toxicologic Veterinary Regulatory Review Pathology (Veterinary Officer / Pathologist) and serves as an authoritative expert in her field, conducting independent, in-depth regulatory reviews and complex safety evaluations of pathology data from regulatory submissions from all FDA Centers. The incumbent performs independent histo-pathological slide evaluations and serves as authoritative expert in regulatory toxicologic veterinary pathology on Center-, Inter Agency-, and national / international professional committees and provides a regulatory perspective when serving on Pathology Working Groups (PWGs) convened to resolve complex pathology issues.

Supervisor: Dennis Keefe, Ph.D., (Director, SSPS, OFAS, CFSAN/FDA)

Senior Toxicologic Veterinary Pathologist, Senior Science and Policy Staff / Pathology  
Department of Health and Human Services / FDA / CFSAN / OFAS /College Park, MD.

2/2007- 3/10. The incumbent serves in the Office of Food Additive Safety (OFAS) in CFSAN as Toxicologic Veterinary Pathologist (Veterinary Officer / Pathologist) conducting independent, in-depth regulatory reviews and complex safety evaluations of pathology data from regulatory submissions from all FDA Centers. The incumbent performs a wide range of administrative functions pertaining to the budget process, property management and pathology contract management.  
Supervisor: Dennis Keefe, Ph.D., (Director, SSPS, OFAS, CFSAN/FDA)

Acting Branch Chief, Pathology Branch

Department of Health and Human Services / FDA / CFSAN / OSAS / DGSS / Pathology Branch, College Park, MD.

1/2005-2/2007 Center-wide Reorganization. The incumbent is an experienced regulatory reviewer and applies in-depth professional knowledge and skills as Veterinary Medical Officer / Pathologist conducting independent safety evaluations of pathology data from regulatory petitions for the Division of General Scientific Support (DGSS).

The incumbent manages independently the Pathology Branch and the associated histopathology laboratory, performing a wide range of administrative functions pertaining to daily operations (such as the budget process, property management and contract management). The Pathology Branch and the Pathology Laboratory provide a full range of pathology support functions

*Updated 02/08/11*

## Curriculum Vitae

### Dr. Sabine FRANCKE-CARROLL

Veterinary Medical Officer / Expert Toxicologic Veterinary Regulatory Review Pathologist

#### PROFESSIONAL EXPERIENCE (contd.):

for requesting Offices/researchers such as pathology protocol design, monitoring animal-study in-life-phases, performing necropsies, guiding the tissue processing, evaluating histological glass slides and reporting of pathology data. The incumbent instructs and trains laboratory associated personnel and adjunct students from the University of Maryland. The incumbent is solely responsible for the development and application of all immuno-histopathological services provided by the Pathology Laboratory.

Supervisor: Prem Dua, D.V.M., Ph.D., (Director, DGSS, OSAS, CFSAN/FDA)

#### Senior Staff Toxicologic Pathologist

Department of Health and Human Services / FDA / CFSAN / OSAS / DGSS / Pathology Branch, College Park, MD.

01/2002-12/2004. The incumbent assists the Director of the Division of General Scientific Support (DGSS) with regulatory (food petition) reviews. To do this the incumbent applies knowledge of FDA laws/regulations and extensive experience in pathology data analysis. The incumbent is further involved in administrative matters pertaining to the operation of the Pathology Branch, e.g. the zero based budgeting process. The incumbent's significant research experience involves her extensively as Co-principal investigator in several research projects with Center and/or adjunct scientists from the University of Maryland (UMD). The incumbent serves as student mentor and instructor to laboratory personnel and UMD/JIFSAN students, and promotes the development of immuno-histopathological services provided by the Pathology Laboratory.

Supervisors: Fred Hines, D.V.M., (Pathology Branch Chief), Prem Dua D.V.M., Ph.D., (DGSS Director)

#### Staff Toxicologic Pathologist

Department of Health and Human Services / FDA / CFSAN / OSAS / DGSS / Pathology Branch, College Park, MD.

01/2001 – 12/2002. The incumbent provides histo-pathological analysis and support to requesting researchers associated with Governmental Offices (e.g. OARSA) and/or joint facilities such as the University of Maryland (under the umbrella of the Joint Institute for Food Safety and Applied Nutrition (JFSAN)). The incumbent participates as Immuno-pathologist and/or as Co-principal-investigator in protocol design, monitors animal-study in-life-phases, performs necropsies, guides the tissue processing, evaluates histological slides and conducts the final pathology-relevant reporting of assigned animal research studies. The incumbent initiates the development of immuno-histopathological services provided by the Pathology Laboratory.

Supervisors: Fred Hines, D.V.M., (Pathology Branch Chief), Prem Dua D.V.M., Ph.D., (DGSS Director)

#### Toxicologic Pathologist, Novartis Pharmaceuticals Inc. East Hanover, NJ.

11/98 –11/2000. The incumbent generates and evaluates pathology data of assigned acute, subacute and chronic preclinical drug-safety studies which also entailed partial, direct/indirect supervision of technical personnel assigned to these studies. The incumbent is assigned to projects with standard design and/or those requiring an appropriate level of interpretive experience and knowledge. A current knowledge of recent advances and new equipment/procedures is important to achieve optimum results. At the conclusion of each study, the incumbent participates in the data review/analyses to determine target organ toxicity. The incumbent participates in the study design and in the evaluation and implementation of new procedures to improve preclinical drug-safety operations. The incumbent is a member of scientific boards, project teams, and advisory committees and performs other duties as assigned by upper management.

Supervisor: Dr. Pritam Sahota, D.V.M, Ph.D.

#### Veterinary Research Pathologist, Pathology Associates International (PAI), Immunology and Molecular Pathology Division Frederick, MD 21701

09/1996 – 98. The incumbent evaluates designs and interprets studies assessing the cross-reactivity characteristics of monoclonal antibodies in human and animal tissues (in vivo/in vitro exposure), the localization of monoclonal antibodies by means of immuno-labeling techniques and conducts development and application of molecular and cellular histopathologic technology to characterize and resolve mechanistic problems associated with biopharmaceutical product development.

Supervisor: Bill Hall, V.M.D., Ph.D.

**PROFESSIONAL EXPERIENCE (contd.):**

Graduate Research Associate (Ph.D. / Veterinary Pathologist), The Ohio State University, Department of Veterinary Biosciences, Columbus, Ohio

1992-1996 Research conducted evaluates anti-retroviral drug-effects (mainly AZT) on cellular immune responses and immune-cell precursor frequencies. Effector-cell frequency analysis, by limiting dilution analysis (LDA), allows not only qualitative assessment but also quantitation of the effects noted. Two animal models, an outbred feline model for retroviral infection and an inbred mouse model for allograft rejection are utilized in these studies. Research activities: Histopathology, immunology, retro-virology, in-vivo and in-vitro drug testing, immunohistochemistry, vaccine development, cell culture and molecular biology.

Thesis advisor: Lawrence E. Mathes, Ph.D., Professor.

Graduate Teaching Associate and Resident (Veterinary Pathologist / Ph.D.)

1990-1992 (continued services during Ph.D training until 1996) The Ohio State University  
Department of Veterinary Biosciences  
Columbus, Ohio

Graduate Assistant (Dr.med.Vet.)

1988-1990 Justus-Liebig University  
Giessen, Germany

Research performed to obtain a "Dr. Vet. Med." degree centers on the immunohistologic characterization of the cellular immune response to bacterial infection with *Coxiella burnetii* in a murine model. Results illustrated that cellular mechanisms are crucially involved in the pathogenesis of chronic infection with *C. burnetii*.

Thesis advisor: Dr. Wolfgang Baumgaertner, D.V.M., Ph.D., Professor.

Graduation from Veterinary School (DVM)

1988 Justus-Liebig University  
Giessen, Germany

**LEADERSHIP EXPERIENCE:**

- Elected board member to IATP 2011: Vice president 2011-13; President 2013-15
- Recognized as Fellow IATP (International Academy of Toxicologic Pathology) 2009.
- FDA recognized (Agency Peer Review) Expert for Toxicologic Veterinary Regulatory Review Pathology (April 2011)
- President Elect of the Association of Government Toxicologists (AGT term 2010-2011)
- Councilor to the Board of the Association of Government Toxicologists (AGT), 2006 & 2008
- CFSAN Immunotox Redbook working group: chair
- STP SRPC Regulatory Liaison since 2005 till present
  - Hepatic Enzyme Induction working group liaison since 2007/ chair – Dec 2008-10
  - Historical Control Data working group SRPC liaison, 2006-2009
- Pathology Laboratory Chief, and Acting Pathology Branch Chief; providing training, instructions and guidance to Laboratory Technicians and visiting scientists from UMD, regarding duties and functions of the Pathology Branch and its Laboratory.
- Mentor to JIFSAN students; Mentor to UMD and Pathology Laboratory students.
- Histopathology mentor and instructor for Laboratory Biologist: training included pathology terminology, histology, histopathology, tissue trimming, tissue processing, preparation of paraffin blocks, microtoming, H&E staining of routine slides, Immunohistochemical staining, archiving, laboratory administrative work and reagent ordering.



**SERVICES AND RESPONSIBILITIES:**

- Regulatory liaison to the Scientific Regulatory and Policy Committee (SRPC) of the Society of Toxicologic Pathology (STP) since 2005
  - SRPC liaison to the Historical Control Data working group; 2006 -09 - Best Practice manuscript published TP 2009; 37(5) 679-93.
  - SRPC liaison to the Hepatic Enzyme Induction Risk Assessment (HEI- RA) working group since 2007; chair since Dec. 2008 – 2010.
  - SRPC liaison to the Joint Regulatory Affairs Committee (JRAC) between STP and the American College of Veterinary Pathology (ACVP); since 2006 - 2009.
  - Invited Member of the STP Regulatory Forum editorial group for the Journal of Toxicologic Pathology since 2007 – ongoing.
- CFSAN Immunotox Redbook committee since 2006
  - Chair: Dec 07 – ongoing.
- Association of Government Toxicologists (AGT)
  - Board member councilor 2005-07; elected for-second term 2008; President elect 2009-10; President 2010-11; Past President 2011-12 – 3 year leadership commitment - ongoing.
- Acting Chief of the Pathology Branch and Laboratory / DGSS (1/2005- until CFSAN reorganization 2/2007).
- CFSAN Cancer Assessment Committee (CAC) Member – Pathologist – since 2004.
- CFSAN Pathology Services and Archiving Contract Project Officer since 2006 – recertified as COTR July 31, 2009.
- Property Management Officer 2005-07.
- CFSAN Science Council Committee Member since 2004.
  - SC Scientific Dissent Resolution policy draft subcommittee 2007-09.
  - SC membership charter following the CFSAN 2007 reorganization subcommittee Scientific Achievement Award-subcommittee (2004, '05, '06, '07, '08).
  - Manuscript clearance subcommittee 2004.
- CFSAN Toxicology Redbook Committee Member since 2003.
- Joint Institute for Food Safety and Applied Nutrition (JIFSAN) steering Committee Member 2002-'07. And JIFSAN Grant – Pathology Support Collaborator to the University of Maryland (UMD), Department of Food Science.

**AWARDS / Professional Recognitions**

- Recognized FDA Expert for Toxicologic Veterinary Regulatory Review Pathology through Agency peer review March 2010.
- Recognized as Fellow IATP (International Academy of Toxicologic Pathology) 2009.
- FDA / CFSAN Outstanding Customer Service Award, Office of Food Additive Safety for *pathology support to CDRH on the histopathological evaluation of mouse tissues for the distribution of nano-material*, June 2008.
- FDA and Center-level Crosscutting Award that includes CFSAN Employees, FDA Melamine Award, Adulterated protein investigations, analysis, planning, scientific review and emergency response team for *exemplary performance to protect the public health from adulterated protein through actions of investigations, sample analyses, method development, assignment, planning, emergency response, scientific review and risk assessment*, June 2008.
- FDA / CFSAN Honor Award: Aspartame Carcinogenicity Review Team, Office of Food Additive Safety for *exceptional performance in evaluating the results of a number of carcinogenicity studies on aspartame, including the high-profile European Ramazzini Foundation study*, June 2008.
- FDA Outstanding Service Award for *outstanding performance while participating on an expert pathology review panel in response to an Inter-Center pathology support request from CDER* June 2007.
- FDA Outstanding Service Award for *outstanding performance in the regulatory review of pathology issues and in providing critical pathology support to the Office of Food Additive Safety* June 2006.
- FDA Outstanding Service Award for *sustained superior performance in evaluating and resolving complex regulatory pathology review issues as well as supporting collaborating scientists* June 2005.
- FDA Outstanding Service Award for *sustained superior performance in the evaluation of substantial and voluminous regulatory and experimental pathology data* June 2004.
- Team Award as member of the OARSA Food Allergenicity Team for *outstanding team effort in successfully completing pilot studies to evaluate a unique animal model for the study of human food allergenicity* June 2003.
- FDA Outstanding Service Award for *sustained superior performance in the Pathology Branch instituting a food-allergy rat model, leveraging with the UMD and establishing a IH laboratory* June 2003

Curriculum Vitae  
**Dr. Sabine FRANCKE-CARROLL**  
Veterinary Medical Officer / Expert Toxicologic Veterinary Regulatory Review Pathologist

- Quality Performance Award for *developing methods to quantify "altered crypt foci" in the colon of rats* July 2002
- Quality Performance Award for *Pathology support services with the University of Maryland (UMD)* June 2002

**PUBLICATIONS AND PRESENTATIONS:**

**Technical Reports:** lists on       - regulatory review projects (upon request)  
  - regulatory research projects (upon request).

**Poster / Journal presentations and Talks:**

Boorman G., Wolf D., Francke-Carroll S., and Maronpot R. Guest Editorial: Pathology Peer Review. Tox Path 38:1009-1010, 2010.

Botts S., Ennulat D., Francke-Carroll S., Graham M., Maronpot R., and Mohutsky M. Introduction to Hepatic Drug Metabolizing Enzyme induction in Drug Safety Evaluation Studies. Tox Path 38: 796-798, 2010.

Mohutsky M., Romeike A., Meador V., Lee W., Fowler J. and Francke-Carroll S. (Chair) Introduction to Hepatic Drug Metabolizing Enzyme induction in Drug Safety Evaluation Studies. Tox Path 38: 799-809, 2010.

Griffis L., Twerdok L.E., Francke-Carroll S., Biles R., Schroeder R., Bolte H., Hall W., Faust H. and Rojko J. Comparative 90-day dietary study of paraffin wax in Fischer-344 and Sprague-Dawley rats. Food and Chemical Toxicology: 2010, 48: 363-372.

Patri A., Umbreit T., Zeng J., Nagashima K., Goering P., Francke-Carroll S., Golden E., Weaver J., Miller T., Sadrieh N., McNeil S., and Stratmeyer M. Energy dispersive X-ray analysis of titanium dioxide nanoparticle distribution after intravenous and subcutaneous injection in mice. Journal of Applied Toxicology 2009, 29: 667-672.

Keenan C., Elmore S., Francke-Carroll S., Kemp R., Kerlin, Peddada, S., R., Pletcher J., Rinke M., Schmidt S., Taylor I. and Wolf D. Potential for a Global Historical Control Database for Proliferative Rodent Lesions. Tox Path 2009; 37(5) 677-8.

Keenan C., Elmore S., Francke-Carroll S., Kemp R., Kerlin, Peddada, S., R., Pletcher J., Rinke M., Schmidt S., Taylor I. and Wolf D. Regulatory Forum: Best Practices for Use of Historical Control Data of Proliferative Rodent Lesions. Tox Path 2009; 37(5) 679-93.

Kerlin R., Hutto D., Silverman L., Francke-Carroll S., Vahle J. Regulatory forum for Toxicologic Pathology: an update. Toxicologic Pathology 2008; 36(5):760.

Austin C., Umbreit T., Brown K., Barber D., Dair B., Francke-Carroll S., Feswick A., Saint-Louis M., Hikawa H., and Goering P. Distribution of iv-injected silver nanoparticles in pregnant mice and developing embryos. Poster presentation at the Society of Toxicology's 48<sup>th</sup> annual meeting held in Baltimore MD, March 15-19, 2009.

Invited Talk: Francke-Carroll S., Society of Toxicologic Pathology (STP), 27<sup>th</sup> annual meeting: As Module of the Effective Communication for the Toxicologic Pathologist - Career Development Courses: "Communicating Pathology Information Effectively to Regulatory Agencies". San Francisco, CA June 20-26, 2008.

Keenan C., Elmore S., Francke-Carroll S., Kemp R., Kerlin R., Pletcher J., Rinke M., Schmidt S., Taylor I., Wolf D. STP Working Group on Historical Control Data of Proliferative Rodent Lesions. Presented at the 26<sup>th</sup> annual meeting of the Society of Toxicologic Pathology (STP) in San Juan, Rio Mar, Puerto Rico, June 2007.

Umbreit T.H., Goering P.L., Miller T.J., Weaver J.L., Francke-Carroll S., Sadrieh N., Kauffman J., Guthrie J., Robertson J., Stratmeyer M.E.: *Toxicity and Tissue Distribution of Titanium Dioxide (TiO<sub>2</sub>) Nanoparticles in subcutaneous and intravenously injected mice over 6 months* Poster presentation at the Society of Toxicology's 47<sup>th</sup> annual meeting held in Seattle, WA, March 21-26, 2008.

Curriculum Vitae  
**Dr. Sabine FRANCKE-CARROLL**  
Veterinary Medical Officer / Expert Toxicologic Veterinary Regulatory Review Pathologist

**PUBLICATIONS AND PRESENTATIONS (contd.)**

Daly K., Tracy A., Francke-Carroll S., Wang T., Malik M. and Magnuson B.A. Enhanced estrogenic responses and sensitivity to azoxymethane following dietary soy isoflavone supplementation in older female rats. *Food Chem Toxicol* 2007 Apr; 45 (4):628-37.

Umbreit T., Goering P., Francke-Carroll S., Patri A., McNeil S., Weaver J., Miller T., Sadrieh N., and Stratmeyer M. *Energy dispersive X-ray analysis of titanium dioxide nanoparticle distribution in mice*. Poster presentation at the Society of Toxicology's 46<sup>th</sup> annual meeting held in Charlotte, NC March 25-29, 2007.

Yoon DM, Hawkins EC, Francke-Carroll S., Fisher JP. Effect of construct properties on encapsulated chondrocyte expression of insulin-like growth factor-1. *Biomaterials* 2007 Jan 28 (2); 299-306.

Morton D, Kemp RK, Francke-Carroll S., Jensen K, McCartney J, Monticello TM, Perry R, Pulido O, Roome N, Schafer K, Sellers R, Snyder PW. Best practice for reporting pathology interpretations within GLP toxicology studies. *Tox Path* 2006; 34 (6); 806-9.

Su Y., Yu T., Lala G., Francke-Carroll S., and Magnuson B.A. Protection of side effects of 5-fluorouracil by anthocyanin-rich extracts. International Research Conference on Food and Nutrition and Cancer, Washington DC, July 2005. Published in *J. Nutr.* 135.12S:3054.

Ferri, M, Francke-Carroll S. and Magnuson B.A. JIFSAN Student project: Development of immuno-histochemical staining techniques for PCNA and APOPTOSIS tissue markers on rat tissues in the CFSAN Pathology Laboratory. Poster presentation at the 11<sup>th</sup> Annual FDA Science Forum, 2005, Washington Convention Center, Washington DC.

Hinton D.M., Lorenzo M., Harper S.B. and Francke-Carroll S., (2004). USFDA, CFSAN, Laurel, MD. Progress in the evaluation of an in-bred rat strain ("asthmatic rat") for predicting the allergic potential of food and other Proteins. Seminar presented at OFAS/CFSAN/USFDA Vermont Ave May 6, 2004.

Hinton D.M., Lorenzo M.E., Harper S.B., Francke-Carroll S., O'Neill R.K., Chirtel S.J., Calvo M.S. An In-Bred Rat Strain (the FDA "Asthmatic Rat") for Predicting the Allergic Potential of Proteins and for Evaluating the Efficacy of Drugs and Dietary Supplements in Respiratory (Asthmatic) and Cardiovascular Studies Poster presentation (Board Number B-08) at the 10<sup>th</sup> Annual FDA Science Forum, 2004, Washington Convention Center, Washington DC.

Magnuson B., Daly K., Malik M., Wang T., Francke-Carroll S. Enhanced Sensitivity of Female Rats to Azoxymethane following Dietary Soy Isoflavone Supplementation. Poster presentation at the 10<sup>th</sup> Annual FDA Science Forum, 2004, Washington Convention Center, Washington DC.

Francke-Carroll S., Daly K., Wang T. and Magnuson B.A. Underlying age-related liver pathology increases azoxymethane toxicity in F344 female rats in an aging study on colon cancer chemoprevention with dietary soy. Website publication (Board Number D-PO-01) for the 10<sup>th</sup> Annual FDA Science Forum, 2004, Washington Convention Center, Washington DC.

Francke-Carroll S., Daly K., Wang T. and Magnuson B.A. Underlying age related liver pathology increases Azoxymethane toxicity in F344 female rats in an aging study on colon cancer and nutrition. Poster presentation # 500 at the Society of Toxicology's 43<sup>rd</sup> annual meeting held in Baltimore, MD, March 21-26, 2004.

Hinton D.M., Lorenzo M., Harper S.B. and Francke-Carroll S., (2004). USFDA, CFSAN, Laurel, MD. Progress in the evaluation of an in-bred rat strain ("asthmatic rat") for predicting the allergic potential of food and other Proteins. , *The Toxicologist* (Platform Session on Hypersensitivity, Abstract #662, 43<sup>rd</sup> Annual Meeting of the Society of Toxicology).

Hinton D.M., Myers M.J., Raybourne R.A., Francke-Carroll S., Sotomayor R.E., Shaddock J., Warbritton A., Chou M.W.: Immunotoxicity of Aflatoxin B<sub>1</sub> in Rats: Effects on Lymphocytes and the Inflammatory Response in a Chronic Intermittent Dosing Study. *Toxicological Sciences*; 73, 362-377, 2003.

Curriculum Vitae  
**Dr. Sabine FRANCKE-CARROLL**  
Veterinary Medical Officer / Expert Toxicologic Veterinary Regulatory Review Pathologist

**PUBLICATIONS AND PRESENTATIONS (contd.)**

Humphreys S.H., Dua P., Francke-Carroll S., Bolger P.M., Calamus: Reassessment of Carcinogenicity. Toxicological Sciences 66, 1-S, 268, 2002.

Francke S., Orosz C.G., Hsu J, and Mathes L.E.: Immunomodulatory Effect of Zidovudine (ZDV) on Cytotoxic T Lymphocytes Previously Exposed to ZDV. Antimicrob Agents Chemother Sept; 46 (9): 2865-71, 2002.

Francke-Carroll, S., Montgomery J.E., Hines F.A., and Magnuson B.A.: The Effect of a Dietary Curcumin Supplement on the Development of Histopathological Age-associated Changes in Male Azoxymethane-Treated F344 Rats. Presented at the twenty-first Annual Symposium of the Society of Toxicologic Pathology, Denver, CO, June. 2-6, 2002.

Francke S., Orosz C.G., Hayes K.A. and Mathes L.E.: Effect of Zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function. Antimicrob Agents Chemother Jul; 44(7): 1900-5, 2000.

Hayes K.A., Phipps A, Francke S. and Mathes L.E.: Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus. Antimicrob Agents Chemother Sep; 44(9): 2399-2405, 2000.

Mathes L.E., Hayes K.A., Francke S. and Phipps A.: Comparison of pathogenesis of the Mount Airy strain of feline immunodeficiency virus (FIV-MD) in pediatric and adult cats. Presented at the Third International Feline Retrovirus Research Symposium, Ft. Collins, CO, March 6-9, 1998.

Francke S. Evaluation of the Immunomodulatory effects of the anti-retroviral drug Zidovudine (AZT). Presented in partial fulfillment of the requirements for the degree Doctor of Philosophy in the Graduate School of The Ohio State University. The Ohio State University, Columbus, OH, USA, 1996.

Francke, S., Hayes K.A., Orosz C.G., and Mathes L.E.: Frequency Analysis of the Immunosuppressive effect of Zidovudine (AZT) on murine lymphocyte function in vitro by Limiting Dilution Analysis (LDA). Presented at the forty-seventh Annual Meeting of The American College of Veterinary Pathologists, Seattle, WA, Dec. 2-6, 1996.

Hayes, K.A., Francke S., Phipps A and Mathes L.E.: AZT therapy in adult cats chronically infected with FIV-MD. Presented at the Third International Feline Retrovirus Research Symposium, Ft. Collins, Co., March 5-9, 1996.

Francke S. and Capen C.C.: Undifferentiated carcinoma in the anterior mediastinum of a dog. Presented at the Eastern North American Veterinary Diagnostic Pathology Conference, Cobleskill, NY, Oct. 21-22, 1995.

Hayes K.A., Wilkinson J.G., Frick R., Francke S. and Mathes L.E.: Early suppression of viremia by ZDV does not alter the spread of feline immunodeficiency virus infection in cats. J Acq Immune Syndr & Hum Retrovir 9:114-22, 1995.

Francke, S. Histological and immunohistological evaluation of the spleen in Balb/cJ (H-2<sup>d</sup>) mice following infection with *Coxiella burnetii*. (Histologische und immunhistologische Untersuchung der Milz von Balb/cJ (H-2<sup>d</sup>)-Mäusen nach Infektion mit *Coxiella burnetii*): Inaugural - Dissertation, Veterinary Medicine, Justus-Liebig-University, Giessen, Germany, 1991.

## **PETER GREAVES MBChB FRCPath**

*Dr Greaves is a medical graduate trained in laboratory medicine, specialising in human and experimental histopathology and toxicology. He has over twenty-five years experience in human and experimental pathology as well as toxicology, pre-clinical drug safety evaluation and drug development. He advises both pharmaceutical companies and government in these areas.*

### **PROFESSIONAL HISTORY:**

#### **CONSULTING PATHOLOGIST**

**March 2005 – present:**

*Advises on preclinical drug safety evaluation and toxicological pathology. Engaged in research in toxicological pathology, carcinogenesis and cancer chemoprevention. Member of the Committee on Carcinogenicity, United Kingdom*

#### **MEDICAL RESEARCH COUNCIL TOXICOLOGY UNIT, LEICESTER**

**March 2000 – February 2005: Senior Research Scientist & Head of Pathology.**

*Responsibility for the histopathological study of disease models and adverse hepatic effects of drugs in obesity in combination with genetic analysis, laser capture dissection microscopy, in situ hybridisation and immunocytochemistry.*

#### **ASTRAZENECA (FORMERLY ZENECA, ICI PHARMACEUTICALS), ALDERLEY PARK, CHESHIRE**

**March 1990 - February 2000: Head of Safety of Medicines Group**

*Responsibility for all preclinical safety studies and kinetics and metabolism work with approximately 300 staff in the UK and US in support of the discovery and development of novel drugs for all of ex-ZENECA Pharmaceuticals.*

#### **ZENECA (FORMERLY ICI) PHARMACEUTICALS, ALDERLEY PARK, CHESHIRE**

**January 1989 - February 1990: Head of Pathology**

*Responsibility for a group of 80 staff conducting histopathological evaluation of toxicity studies.*

#### **PARKE-DAVIS RESEARCH INSTITUTE, MISSISSAUGA, ONTARIO, CANADA**

**January 1987 - December 1988: Director of Research Institute**

*Responsibility for the Sheridan Park Research Laboratory (60 staff) undertaking preclinical safety studies for Parke-Davis Research centred at Ann Arbor, Michigan.*

#### **WELLCOME RESEARCH LABORATORIES, BECKENHAM, KENT, ENGLAND**

**January 1985 - December 1986: Head of Toxicology and Metabolism**

*Responsibility for drug safety evaluation, preclinical drug kinetics and radiochemistry at the Beckenham site (50 staff), in collaboration with Experimental Pathology and Toxicology at Research Triangle Park site.*

#### **CENTRE DE RECHERCHE, LABORATOIRES PFIZER, AMBOISE, FRANCE**

**September 1981 - December 1984: Director of Pathology**

**April 1979 - August 1981 - Pathologist**

**WESTMINSTER HOSPITAL MEDICAL SCHOOL & ST STEPHEN'S HOSPITAL,  
LONDON**

September 1976 - March 1979 - Senior Registrar in Histopathology

February 1975 - February 1976 - Registrar in Histopathology

**MEDIZINISCHE HOCHSCHULE, HANNOVER, GERMANY.**

February 1976 - September 1976 - Assistant in Pathology

**NEWCASTLE GENERAL HOSPITAL, NEWCASTLE-UPON-TYNE**

September 1972 - February 1975 - Senior House Officer in Pathology

**GRAVESEND HOSPITAL, KENT**

October 1972 - May 1972 - House Physician

**CHICHESTER HOSPITAL, WEST SUSSEX**

February 1971 - August 1971 - House Surgeon

**EDUCATION AND DEGREES:**

- \* MBChB University of Birmingham, England, 1969
- \* MRCPPath in human histopathology, Royal College of Pathologists, London, 1977
- \* FRCPath in histopathology & toxicology, Royal College of Pathologists, London, 1989
- \* GMC Registration in Morbid Anatomy and Histopathology under the European Specialist Medical Qualifications order 1995 (number 1491454)
- \* Medical Defence Union membership (membership number 095078D)

**OTHER ACTIVITIES:**

- \* Member of the *Committee on Carcinogenicity*, United Kingdom 2008-present
- \* Member of *International Life Sciences Institute (ILSI) – Europe* project on data selection for modelling of substances that are genotoxic and carcinogenic 2009-2011
- \* Chairman of *International Harmonization of Nomenclature and Diagnostic Criteria* committee for rodent soft tissue pathology 2009-present
- \* Member of the *Veterinary Products Committee* of the United Kingdom 2003-2007
- \* Member of the editorial board for *Toxicologic Pathology* 2002-2006
- \* Member of the editorial board for *Experimental & Toxicologic Pathology* 2000-2007.
- \* Chairman of *Zeneca Leisure* 1996-1999: This group managed all the company leisure activities, clubs and leisure facilities, turnover £1 million per annum
- \* Member of Personnel steering group for *Zeneca R&D* in the UK 1996-1999
- \* Member of Health & Safety Steering Committee for the Alderley Park R&D site 1996-1999
- \* Biological Safety Officer, MRC Toxicology Unit 2000-2003

**Date:** 21 July 2010

## PUBLICATIONS:

### Books:

Greaves P. and Faccini J.M. (1992): *Rat Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies*, 2<sup>nd</sup> edition. Elsevier, Amsterdam.

Greaves P. (2007): *Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation*. Elsevier, Amsterdam. 3<sup>rd</sup> edition.

### Main scientific papers:

Greaves P., Filipe M.I. and Branfoot A.C. (1980): Transitional mucosa and survival in human colorectal cancer. *Cancer*, **46**, 764-770.

Greaves P. and Faccini J.M. (1981): Fibrous histiocytic neoplasms spontaneously arising in rats. *Br.J.Cancer*, **43**, 402-411.

Greaves P., Martin J. and Masson M-T. (1982): Spontaneous rat malignant tumors of fibrohistiocytic origin. An ultrastructural study. *Vet.Pathol.*, **19**, 497-505.

Greaves P. and Rabémampianina Y. (1982): Choice of rat strain: A comparison of the general pathology and tumour incidence in 2-year old Sprague-Dawley and Long-Evans rats. In: *New Toxicology for Old*, *Arch.Toxicol.*, Suppl **5**, 298-303.

Villanove F. and Greaves P. (1983): Sialoglycoconjugates in normal and neoplastic rat liver: A histochemical study. *Pathol.Res.Pract.*, **178**, 171.

Michel M.C., Greaves P., Martin J. and Greaves P. (1983): Etude ultrastructurale des lymphomes malins non Hodgekiniens gastrointestinaux spontanés chez le hamster Syrien (*Mesocricetus auratus*). *Biol.Cell.*, **48**, 10a.

Greaves P., Martin J., Michel M.C. and Mompon P. (1984): Cardiac hypertrophy in dog and rat induced by oxfenicine an agent which modifies muscle metabolism. In: *Diseases, Metabolism and Reproduction in the Toxic Response to drugs and Other Chemicals*. *Arch.Toxicol.*, Suppl. **7**, 488-493.

Irisarri E., Kessedjian M.J., Charuel C., Faccini J.M., Greaves P., Monro A.M., Nachbaur J. and Rabémampianina Y. (1984): The preclinical toxicity of Dazoxiben, a specific inhibitor of thromboxane A2 synthetase. In: *Disease, Metabolism and Reproduction in the Toxic Response to Drugs and Other Chemicals*. *Arch.Toxicol.*, Suppl. **7**, 363-364.

Taradach C. and Greaves P. (1984): Spontaneous eye lesions in laboratory animals. Incidence in relation to age. *CRC Crit.Rev.Toxicol.*, **12**, 121-147.

Greaves P. and Boiziau J.L. (1984): Altered patterns of mucin secretion in gastric hyperplasia in mice. *Vet.Pathol.*, **21**, 224-228.

Greaves P., Filipe M.I., Abbas S. and Ormerod M.G. (1984): Sialomucins and carcinoembryonic antigen in the evolution of colorectal cancer. *Histopathology*, **8**, 825-834.

Irisarri E., Kessedjian M.J., Charuel C., Faccini J.M., Greaves P., Monro A.M., Nachbaur J. and Rabémampianina Y. (1985): Dazoxiben, a prototype inhibitor of thromboxane synthesis, has little toxicity in laboratory animals. *Hum.Toxicol.*, **4**, 311-315.

Higgins A.J., Faccini J.M. and Greaves P. (1985): Coronary hyperemia and cardiac hypertrophy following inhibition of fatty acid oxidation. Evidence of a regulatory role for cytosolic phosphorylation potential. In: N.S. Dhalla and D.J. Hearse (Eds), *Advances in Myocardiology*, Vol. **6**, pp. 329-338, Plenum.

Greaves P., Martin J.M. and Rabémampianina Y. (1985): Malignant fibrous histiocytoma in rats at site of implanted millipore filters. *Am.J.Pathol.*, **120**, 207-214.

Spencer A.J. Andreu M. and Greaves P. (1986): Neoplasia and hyperplasia of pancreatic endocrine tissue in the rat: An immunocytochemical study. *Vet.Pathol.*, **23**, 11-15.

Greaves P., Irisarri E. and Monro A.M. (1986): Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbitone: Their rate of onset and their reversibility. *J.N.C.I.*, **76**, 475-484.

Masson M.T., Villanove F. and Greaves P. (1986): Histological demonstration of wheat germ lectin binding sites in normal and ANIT-treated rats. *Arch.Toxicol.*, **59**, 121-123.

Spencer A. and Greaves P. (1987): Polyarteritis in a beagle dog colony. *J.Comp.Pathol.*, **97**, 122-128.

Mompon P., Greaves P., Irisarri E., Monro A.M. and Bridges J.W. (1987): A cytochemical study of the livers of rats treated with diethylnitrosamine/phenobarbital, with benzidine/phenobarbital, with phenobarbital, or with clofibrate. *Toxicology*, **46**, 217-236.

Greaves P. (1987): Safety evaluation prior to administration of drugs to man. *Lab.Anim.*, **21**, 166.

Greaves P. (1989): Malignant fibrous histiocytoma, rat. In: Monograph on Pathology of Laboratory Animals. Integument and Mammary Glands. T.C. Jones, U.Mohr and R.D. Hunt (Eds), pp.106-112. Springer-Verlag, Berlin.

de la Iglesia F.A. and Greaves P. (1989): Role of toxicokinetics in drug safety evaluations. In: Toxicokinetics and New Drug Development. A. Yacobi J.P. Skelly and Y.K. Batra (Eds), chap 2, pp 21-32, Pergamon Press, New York.

Macallum G.E., Smith G.S., Barsoum N.J., Walker R.M. and Greaves P. (1989): Renal and hepatic toxicity of a benzopyran-4-one in the cynomolgus monkey. *Toxicology*, **59**, 97-108.

Albassam M.A., Houston B.J., Greaves P. and Barsoum N.J. (1989): Polyarteritis in a beagle. *J.Am.Vet.Med.Assoc.*, **194**, 1595-1597.

Macallum G.E., Walker R.M., Barsoum N.J., Smith G.S. and Greaves P. (1989): Preclinical toxicity studies of an adenosine agonist, CI-936. *Toxicologist*, **9**, 178.

Walker R.M., Clarke D.W., Smith G.S., Macallum G.E. Barsoum N.J. and Greaves P. (1989): Hepatotoxicity of tacrine in animal models. *Toxicologist*, **9**, 197.

Greaves P. and Barsoum N. (1990): Tumours of soft tissues. In: Pathology of Tumours of Laboratory Animals, Vol 1, Tumours of the Rat. V.S. Turusov and U. Mohr (Eds), 2nd Edition, pp 597-623, IARC, Lyon.

Westwood F.R., Greaves P. and Iswaran T.J. (1990): Arterial and venous changes in rats following administration of a phosphodiesterase inhibitor. *Toxicol.Pathol.*, **18**, 699.

Westwood F.R., Iswaran T.J. and Greaves P. (1990): Pathologic changes in blood vessels following administration of an inotropic vasodilator (ICI 153,110) to the rat. *Fundam.Appl.Toxicol.*, **14**, 797-809.

Westwood F.R., Iswaran T.J. and Greaves P. (1991): Long-term effects of an inotropic phosphodiesterase inhibitor (ICI 153,110) on the rat salivary gland, Harderian gland and intestinal mucosa. *Toxicol.Pathol.*, **19**, 214-223.

Greaves P., Faccini, J.M. and Courtney C.L. (1992): Proliferative lesions in soft tissues in rats, MST-1. In: Guides for Toxicologic Pathology, STP/ARP/AFIP, Washington DC.

Carlton, W.W., Ernst, H., Faccini, J.M., Greaves, P., Krinke, G.L., Long, P.H., Maekawa, A., Newsholme, S.J. and Weisse, G. (1992): Soft tissue and musculoskeletal system. In: Mohr, U., Capen, C.C., Dungworth, D.L., Griesemer,



R.A., Ito, N., and Turusov, V.S. (Eds.) International Classification of Rodent Tumours, Part I, The Rat. IARC Scientific Publication No. 122, Lyon.

Lazenby C.M., Westwood F.R. and Greaves P. (1993): Crescentic cataracts in Alderley Park rats. *Vet.Pathol.*, **30**, 70-74.

Greaves, P., Goonetilleke, R., Nunn, G., Topham, J and Orton, T. (1993): Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. *Cancer Res.*, **53**, 3919-3924

Greaves P. (1993): Pathological techniques in toxicology. In: General and Applied Toxicology. B. Ballantyre, T. Marrs, and P. Turner (Eds), vol. 1, chap. 12, pp. 245-265, Stockton Press, New York.

Greaves P. (1995): Pathological techniques in toxicology. In: General and Applied Toxicology. B. Ballantyre, T. Marrs, and P. Turner (Eds), abridged edition, chap. 10, pp. 225-245, Stockton Press, New York.

Greaves P. (1996): The evaluation of potential human carcinogens: A histopathologist's view. *Exp.Toxicol.Pathol.*, **48**, 169-174.

Greaves P. and Seely J.C. (1996): Non-proliferative lesions of soft tissues and skeletal muscle in rats, MST-1. In: Guides for Toxicologic Pathology, STP/ARP/AFIP, Washington, DC.

Greaves P. (1997): Tumors of soft tissues including cardiovascular system. In: Pathology of Neoplasia and Preneoplasia in Rodents. P. Bannasch and W. Gössner (Eds), chap. 12, pp. 183-201, EULEP Color Atlas, vol. 2, Schattauer, Stuttgart.

Greaves P. (1997): Urinary system. In: Target Organ Pathology: A Basic Text. J.A. Turton and J. Hooson (Eds), chap. 4, pp. 99-139, Taylor and Francis, London.

Greaves P. (1998): Patterns of drug-induced cardiovascular pathology in the beagle dog: relevance for humans. *Exp.Toxicol.Pathol.* **50**, 283-293.

Greaves P. (1999): Pathological techniques in toxicology. In: General and Applied Toxicology. B. Ballantyre T. Marrs and T. Syversen, (Eds), chap. 16, pp. 335-353, 2<sup>nd</sup> Edition. Stockton Press, New York.

Greaves P. (2000): Patterns of cardiovascular pathology induced by diverse cardioactive drugs. *Toxicol.Lett.*, **112-113**, 547-552.

Ernst, H., Carlton, W.W., Courtney, C., Rinke, M., Greaves, P., Isaacs, K.R., Krinke, G., Konishi, Y., Mesfin, G.M. and Sandusky, G. (2001): Soft tissue and skeletal muscle. In: Mohr, U. (Ed), International Classification of Rodent Tumours. The Mouse, pp. 361-388. Springer Verlag, Heidelberg.

Pyrah, I.T., Kalinowski, A., Jackson, D., Davies, W., Aldridge, A. and Greaves, P. (2001): Pathology of two structurally related inhibitors of oxidosqualene cyclase in the dog and mouse. *Toxicol.Pathol* **29**, 174-179.

Greaves, P., Edwards, R., Cohen, G.M. and MacFarlane, M. (2001): Have you seen this? Diffuse hepatic apoptosis. *Toxicol.Pathol.*, **29**, 398-400.

Parrott, E., Butterworth, M., Green, A., White I.N.H. and Greaves P. (2001): Adenomyosis - a result of disordered stromal differentiation. *Am.J.Pathol*, **159**, 623-630.

Green, A.R., Parrott, E.L., Butterworth, M., Jones, P.S., Greaves, P. and White I.N.H. (2001): Comparisons of the effects of tamoxifen, toremifene and raloxifene on enzyme induction and gene expression in the ovariectomized rat uterus. *J.Endocrinol.*, **170**, 555-564.

Edwards, R., Colombo, T. and Greaves P. (2002): Have You Seen This?" Peliosis Hepatis. *Toxicol.Pathol.*, **30**, 521-523.

- Donald, S., Verschoyle, R., Edwards, R., Judah, D.J., Davies R., Riley J., Dinsdale, D., Lazaro L.L., Smith, A.G., Gant, T.W. Greaves, P. and Gescher, A.J. (2002): Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat. *Cancer Res*, **62**, 4256-4262.
- Gant, T.W., Baus, P.R., Clothier, B., Riley, J., Davies, R., Judah, D.J., Edwards, R.E., George, E., Greaves, P. and Smith, A.G. (2003): Gene expression profiles associated with inflammation, fibrosis and cholestasis in mouse liver after griseofulvin. *Environ. Health Persp.* **111**, 847-853
- Green, A.R., Edwards, R.E., Greaves, P. and White, I.N.H. (2003): Comparison of the effect of oestradiol, tamoxifen and raloxifene on nerve growth factor alpha expression in specific neonatal mouse uterine cell types using laser capture microdissection. *Journal of Molecular Endocrinology* **30**, 1-11.
- Jones, H.B., Macpherson, A., Siddall, R., Betton, G.R., Davis, A.S. and Greaves, P. (2003): Endothelin antagonist-induced coronary and systemic arteritis in the beagle dog. *Toxicol.Pathol.* **31**, 263-272.
- Donald, S. Verschoyle, R.D., Greaves, P., Gant, T.W., Colombo, T., Zaffaroni, M., Frapolli, R., Zucchetti, M., D'Incalci, M., Meca D., Riccardi, R., Lopez-Lazaro, L., Jimeno, J. and Gescher, A.J. (2003): Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the Rat. *Cancer Res.* **63**, 5902-5908.
- Damment, S.J.P., Greaves, P. and Downs, N. (2003): The toxicology of lanthanum carbonate, a new non-aluminium, non-calcium phosphate binder. *Journal of the American Society of Nephrology* **14**, 204A
- Verschoyle, R.D., Edwards, R., Nolan, B. and Greaves, P. (2004): Articular chondromatosis and chondroid metaplasia in transgenic TAG mice. *Toxicol.Pathol.* **32**:22-25.
- Donald, S., Verschoyle, R.D., Greaves, P., Orr, S., Lopez-Lazaro, l., Jimeno, J. and Gescher A.J. (2004): Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes *in vitro*. *Cancer Chemother. Pharmacol.* **53**, 305-312.
- Greaves, P., Williams, A. and Eve M. (2004): First dose of potential new medicines to humans: learning from animals. *Nature Rev Drug Discovery* **3**, 226-236.
- Donald, S., Verschoyle, R. D., Greaves, P., Colombo, T., Zucchetti, M., Falcioni, C., Zaffaroni, M., D'Incalci, M., Manson, M.M., Jimeno, J., Steward, W.P. and Gescher A.G. (2004): The chemopreventive agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug yondelis (ET-743) without compromising efficacy in a rat mammary carcinoma. *Int. J Cancer* **111**, 961-967.
- Cai, H., Hudson, E.A., Mann, P., Verschoyle, R.D., Greaves, P., Manson, M.M. Steward W.P. and Gescher A.J. (2004): Growth-inhibitory and cell cycle-arresting properties of the rice bran constituent tricin in human-derived breast cancer cells *in vitro* and in nude mice *in vivo*. *Brit. J. Cancer* **91**, 1364-1371.
- Gant, T.W., Greaves, P., Smith, A.G. and Gescher A. (2005): Toxicogenomics applied to understanding cholestasis and steatosis in the liver. In: Jürgen Bortak (Ed). *Toxicogenomics*, chap. 15, pp 369-394, Wiley-VCH Verlag, Weinheim.
- Green, A.R. Styles, J.A., Parrott, E.L., Gray, D., Edwards, R.E., Smith, A.G., Gant, T.W. Greaves, P., Al-Azzawi, F. and White, I.N.H (2005): Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer. *Expt. Toxicol. Pathol.* **56**, 255-263.
- Davies, R., Schuuman A., Barker, C.R., Clothier B., Chernova, T., Higginson, F.M., Judah, D.J., Dinsdale, D., Edwards, R.E. Greaves, P., Gant, T.W. and Smith A.G. (2005). Hepatic gene expression in protoporphyric *Fech* mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool. *Am.J.Pathol*, **166**, 1041-1053.

- Greaves, P., Clothier, B., Davies, R., Higginson, F.M., Edwards, R.E., Dalton, T.P., Nebert, D.W. and Smith, A.G. (2005): Uroporphyrin and hepatic carcinogenesis induced by polychlorinated biphenyls-iron interaction: absence in the *Cyp1a2*(-/-) knockout mouse. *Biochemical and Biophysical Research Communications* **331**, 147-152
- Cai, H., Al-Fayez, M., Tunstall, R.G., Platten, S., Greaves, P., Steward, W.P. and Gescher, A.J. (2005): The rice bran constituent tricin potentially inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in *ApcMin* mice. *Mol.Cancer Ther.*, **4**, 1287-1292.
- Greaves, P. (2005): Animals in the safety testing of new therapies. *School Science Review*, **87**, 99-104.
- Verschoye, R.D., Greaves, P., Cai, H., Borkhardt, A., Broggini, M., D'Incalci, Riccio, E., Doppalapudi, R., M., Kapetanovic, I., Steward, W.P. and Gescher, A.J. (2006): Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. *Cancer Chemother.Pharmacol.*, **57**, 1-6.
- Greaves, P. and White, I.N. (2006): Experimental adenomyosis. *Best Practice & Research Clinical Obstetrics & Gynaecology*, **20**, 503-510.
- Ridd, K., Zhang, S-D., Edwards, R.E., Davies, R., Greaves, P., Wolfreys, A., Smith A.G. and Gant, T.W. (2006): Association of gene expression with sequential proliferation, differentiation and tumour formation in murine skin. *Carcinogenesis*, **8**, 1556-1566
- Verschoye, R.D., Greaves, P., Cai, H., Edwards, R.E. Steward, W.P. and Gescher, A.J. (2007): Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis. *Br.J.Cancer*, **96**, 248-254.
- Kaur, S., Greaves, P., Cooke, D., Edwards, R., Steward, W.P., Gescher, A.J. and Marczylo, T.H. (2007): Breast cancer prevention by green tea catechins and black tea theaflavins in the C3(1) SV40 T,t antigen transgenic mouse model is accompanied by increased apoptosis and a decrease in oxidative DNA adducts. *Journal of Agricultural and Food Chemistry*, **55**, 3378-3385.
- Razvi, N., Greaves, P., Styles, J., Edwards, R., and White, I. N.H. (2007): Absence of uterine tumours in CD-1 mice treated neonatally with subcutaneous tamoxifen or 4-hydroxyoestradiol. *Experimental and Toxicologic Pathology*, **59**, 177-185
- Hardisty, J., Elwell, M., Ernst, H., Greaves, P., Kolenda-Roberts, H., Malarkey, D., Mann, P.C., Tellier, P. (2007): Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists. *Toxicologic Pathology*, **35**, 928-941.
- Pathak, S.K., Singh, R., Verschoye, R.D., Greaves, P., Farmer, P.B., Steward, W.P. J K Mellon, J.K., Gescher, A.J., Sharma, R.A. (2008): Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown *in vitro* and *in vivo*. *Cancer Letters*, **261**, 74-83
- Davies, R., Clothier, B., Robinson, S., Edwards, R., Greaves, P., Luo, J-L., Gant, T., Chernova, T. and Smith, A. (2008): Essential role of the AH-receptor in the dysfunction of heme metabolism induced by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin. *Chemical Research in Toxicology*, **21**, 330-340.
- Greaves, P. (2008): Preclinical testing. In: *Encyclopedia of Cancer*, 2<sup>nd</sup> edition, (ed. M. Schwab), Springer-Verlag, Heidelberg.
- Verschoye, R.D., Greaves, P., Patel, K., Marsden, D., Brown, K., Steward, W.P. and Gescher, A.J. (2008): Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels. *European Journal of Cancer*, **21**, 898-906.
- Teichert, F., Verschoye, R.D., Greaves, P., Edwards, R.E., Teahan, O., Jones, D., Wilson, I.D., Farmer, P.B., Steward, W.P., Gant, T.W. and Gescher, A.J. Keun, H.C (2008): Metabolic profiling of transgenic adenocarcinoma of mouse

prostate (TRAMP) tissue by  $^1\text{H}$ -NMR analysis—evidence for unusual phospholipid metabolism. *Prostate*, **68**, 1035-1047.

Teichert, F., Verschoyle, R.D., Greaves, P., Thorpe, J.F., Mellon, J.K., Steward, W.P., Farmer, P.B., Gescher, A.J. and Singh, R. (2009): Determination of 8-oxo-2-deoxyguanosine and creatinine in murine and human urine by liquid chromatography-tandem mass spectrometry: application to chemoprevention studies. *Rapid Communications in Mass Spectrometry*, **23**, 258-266.

Greaves P. (2009): Pathological techniques in toxicology. In: General and Applied Toxicology, pp 691-706, B. Ballantyre T. Marrs and T. Syversen, (Eds), 3<sup>rd</sup> Edition. John Wiley and Sons Ltd., Chichester.

Howells, L.M., Britton, R.G., Mazzeletti, M., Greaves, P., Broggin, M., Brown, B., Steward, W.P., Gescher, A.J., Sale, S. Preclinical colorectal cancer chemopreventive efficacy and p53-modulating activity of 3',4',5'-trimethoxyflavonol, a quercetin analog. *Cancer Prevention Research*. **In press**

Bruner R., Greaves, P., Hard G.C., Regan, K., Ward, J.M., David, R.M. Histopathologic changes in the kidneys of male F344 rats from a 2-year inhalation carcinogenicity study of tetrahydrofuran. A pathology working group review and re-evaluation. *Regulatory Toxicology and Pharmacology*. **In press**. Online publication: 31 May 2010

Teichert, F., Verschoyle, R.D., Greaves, P., Jones, D.J.L., Wilson, I.D., Farmer, P.B. Steward, W.P., Gescher, A.J., and Keun H.C. Plasma metabolic profiling reveals age-dependency of systemic effects of green tea polyphenols in mice with and without prostate cancer. *Molecular BioSystems*. **In press**



Experimental Pathology Laboratories, Inc.

---

**JERRY F. HARDISTY**  
**CHIEF EXECUTIVE OFFICER/SENIOR PATHOLOGIST**

**EDUCATION:**

Iowa State University, Pre-Veterinary, 1965-1967

Iowa State University, D.V.M., 1971

Certified by the American College of Veterinary Pathologists, 1976

Adjunct Associate Professor at the School of Veterinary Medicine,  
NC State University, 1983

**PRESENT POSITION AND EXPERIENCE:**

2010 - Present. Chief Executive Officer/Veterinary Pathologist, Experimental Pathology Laboratories, Inc., Research Triangle Park, North Carolina

Responsible for the overall implementation of the strategic goals and objectives of EPL. Provide leadership toward the company's philosophy, mission, strategy, and goals and objectives. Direct the company's business development and marketing efforts. Serve as the Principal Investigator as a Study Pathologist, Peer Review Pathologist and Chairperson for Pathology Working Groups and Scientific Advisory Panels.

1998 - 2010. President and Veterinary Pathologist, Experimental Pathology Laboratories, Inc., Research Triangle Park, North Carolina

Responsible for overall management and direction of contract research pathology laboratories in Virginia and North Carolina. The company serves both government and university research and the safety assessment programs of the pharmaceutical, chemical, and cosmetic industries.

1994 - 1998. Vice President, Operations and Pathologist, Experimental Laboratories, Inc., Research Triangle Park, North Carolina

Responsible for overall management and direction of pathology research laboratories in North Carolina and Virginia.

1978 - 1994. Director and Pathologist, Experimental Pathology Laboratories, Inc., Research Triangle Park, North Carolina

Responsible for the project management, direction and technical supervision of the North Carolina branch of EPL. Responsible for the microscopic evaluation of toxicological studies. Responsible for the National Toxicology Program's Pathology Quality Assessment Program and Operations of the NTP Archives.

1976 - 1978. Pathologist/Project Manager, Experimental Pathology Laboratories, Inc., Herndon, Virginia

Responsible for the management of EPL's Carcinogenesis Support Laboratory. Project Manager of a program to provide Tracor Jitco with Quality Assurance in the NCI Carcinogenesis Testing Program. Technical supervision of a program to provide pathology support services to the Carcinogenesis Program of the National Cancer Institute. Responsible for the microscopic evaluation of tissues from experimental animals used in a variety of toxicological studies.



**JERRY F. HARDISTY, DVM, DACVP**

**PRESENT POSITION AND EXPERIENCE – Continued**

1972-1976      Research Pathologist, Veterinary Pathology Branch, Biomedical  
Laboratory, Edgewood Arsenal, Maryland

Dr. Hardisty was a preceptee in the U.S. Army preceptorship program in Veterinary Pathology. During this time he performed gross and microscopic diagnoses of spontaneous disease and changes produced by experimental procedures in laboratory animals. He prepared reports describing and interpreting these experimental results.

During this time he was principal investigator for the reproductive, mutagenic, teratogenic studies performed at the laboratory. This work consisted of revising previous experimental protocols and designing new experimental protocols to be utilized at the laboratory. The experimental design employed required the gross examination of pregnant female rats and fetuses for evidence of fetal toxicity and teratogenesis. He trained biological technicians to perform timed matings in rats, examine serially sectioned fetuses for malformations, and to examine fetal skeletons for prenatal abnormalities.

1971-1972      Attending Veterinarian, Division of BioSensor Research,  
Walter Reed Army Institute of Research

Dr. Hardisty studied the radiographic and morphologic lesions of several musculoskeletal diseases of the German Shepherd Dog. In association with Dr. Wayne Riser, he investigated the pathogenesis and possible genetic relationship of canine hip dysplasia, eosinophilic panosteitis and ununited anconeal processes in an attempt to reduce their incidence through a selective breeding program.

**PROFESSIONAL MEMBERSHIPS:**

Diplomate, American College of Veterinary Pathologists

ACVP Subspecialty in Toxicologic Pathology

American College of Toxicology

Society of Toxicology

Society of Toxicologic Pathologists

British Society of Toxicologic Pathologists

International Academy of Toxicologic Pathology

American Veterinary Medical Association

North Carolina Society of Toxicology

Charles Louis Davis, D.V.M. Foundation

The Society of Phi Zeta

The Society of Gamma Sigma Delta

The Fraternity of Alpha Zeta

The Fraternity of Omega Tau Sigma

American Association for the Advancement of Science

Standardized System of Nomenclature and Diagnostic Criteria (SSNDC), The



**JERRY F. HARDISTY, DVM, DACVP**

**PROFESSIONAL ACTIVITIES – Continued**

Society of Toxicologic Pathologists, 1987-1995.  
Executive Committee, The Society of Toxicologic Pathologists, 1994- 1998.  
Executive Committee Chairman, The Society of Toxicologic Pathologists, 1997-1998.  
Joint Committee for STPs/ILSI on International Standardization of  
Nomenclature and Diagnostic Criteria for Toxicologic Pathology, 1994-1995,  
Co-Chairman 1995-Present.  
President-Elect, The Society of Toxicologic Pathologists, 1999-2000.  
President, The Society of Toxicologic Pathologists, 2000-2001.  
Past President, The Society of Toxicologic Pathologists, 2001-2002.  
Long Range Planning Committee, American College of Toxicology, 2002.  
North American Director, International Academy of Toxicologic Pathology, 2002.  
FDA Clinical Pharmacology Subcommittee of the Advisory Committee for  
Pharmaceutical Sciences, FDA Center for Drug Evaluation and Research, 2003.

**EDITORIAL REVIEW BOARD:**

International Agency for Research on Cancer (WHO), Classification of Rodent Tumors, Part II,  
The Mouse, 1995-2001.  
  
*Editorial Review Board for Fundamental and Applied Toxicology, Society of Toxicology Board of  
Publications, 1996-1998.*  
  
*Editorial Review Board for Toxicological Sciences, Society of Toxicology Board of Publications,  
1998-2004.*  
  
*Editorial Review Board for Experimental and Toxicologic Pathology, 2000.*  
  
*Editorial Board of Toxicologic Pathology, 2006-2008.*

**PUBLICATIONS AND PAPERS:**

Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid, Hormone 1-84 in a 2-  
Year Study in Fischer 344 Rats. The Society of Toxicologic Pathology  
  
Factors predisposing to urolithiasis in feedlot cattle. Hardisty JF and Dillman RC. The Iowa  
State University Veterinarian, Iowa State University, Ames, Iowa, 33(2), 77-81, 1971.  
  
Reduction of frequency of hip dysplasia in military dogs. Riser WH, Hardisty JF and Castleberry  
MW. In Proceedings, Canine Hip Dysplasia Symposium and Workshop, OFA, Columbia, MO.  
1972.  
  
Genetic influence of the male on the incidence of canine hip dysplasia. Hardisty JF, Scalera  
SE., Castleberry MW and Riser WH. In Proceedings, Canine Hip Dysplasia Symposium and  
Workshop, OFA, Columbia, MO. 1972.



**JERRY F. HARDISTY, DVM, DACVP**

**PUBLICATIONS AND PAPERS – Continued**

Evaluation of the effects of chemical compounds on the reproductive system of rats. Hardisty JF. Presented at the Biomedical Laboratory Review and Analysis, April 1975.

Reproductive studies with quint essence compounds. Hardisty JF, Presented at the Biomedical Laboratory Review and Analysis of Quint Essence, January 1976.

Effects of KZ/IP mixture on the reproductive system. Hardisty JF and Pellerin RJ. Edgewood Arsenal Technical Report, 1976.

Reproductive studies with diisopropylmethylphosphate in rats. Hardisty JF, Pellerin RJ, Biskup RF and Manthei JH. Edgewood Arsenal Technical Report ARCSL TR 77037, May 1977.

Quality assurance in pathology. Hardisty JF, Ward JM and Griesemer RA. NCI-NCTR Pathology Workshop, Bethesda, MD, June 1978.

Mononuclear cell leukemia in Fischer 344 rats. Hardisty JF. NCI-NCTR Pathology Workshop, Bethesda, MD, June 1978.

Quality assurance for pathology in rodent carcinogenesis tests. Ward JM, Goodman DG, Griesemer RA, Hardisty JF, Schueler RL, Squire RA and Strandberg JD. Journal of Environmental Pathology and Toxicology, 2, 371-378, Nov.-Dec. 1978.

Neoplasms and pigmentation of the thyroid gland in F-344 rats exposed to 2,4-diaminoaniline sulfate, a hair dye component. Ward JM, Stinson, SF, Hardisty JF, Cockrell BY and Hayden DW. Journal of the National Cancer Institute, Vol. 62, No. 4, 1979. Apr;62(4) 1067-73

Renal carcinogenic and nephrotoxic effects of the flame retardant TRIS[(2,3-dibromopropyl) phosphate] in F-344 rats and B6C3F1 mice. Reznik G, Ward JM, Hardisty JF and Russfield A. Journal of the National Cancer Institute, Vol. 63, No. 1, July 1979.

Correlation between gross observations of tumors and neoplasms diagnosed microscopically in carcinogenesis bioassays in rats. Kulwich BA, Hardisty JF, Gilmore CE and Ward JM. Journal of Environmental Pathology and Toxicology, 3, 281-287, December 1979.

Evaluation of procedures suggested for reducing the pathology workload in a carcinogenesis testing program. Hardisty JF, Ward JM, Douglas JF and Fears TR. Journal of Environmental Pathology and Toxicology, 3, 167-176, December 1979.

Cancer induction following single and multiple exposures to a constant amount of vinyl chloride monomer. Hehir RM, McNamara BP, McLaughlin J, Willigan DA, Bierbower G and Hardisty JF. Presented for the conference to re-evaluate the Toxicology of Vinyl Chloride Monomer, Polyvinyl Chloride and Structural Analogues on March 20-21, 1980, at the National Institute of Health, Bethesda, MD.

Cancer induction following single and multiple exposures to a constant amount of vinyl chloride monomer. Hehir RM, McNamara BP, McLaughlin J, Willigan DA, Bierbower G and Hardisty JF. Environmental Health Perspectives, 41, 63-72, October 1981.

Carcinogenesis bioassay of 2,6-Xylidine in rats. Hardisty JF, Montgomery CA and Kornreich M. The Toxicologist, Vol 3, No. 1, March 1983.

Chronic toxicity and oncogenicity bioassay of inhaled toluene in Fischer 344 rats. Gibson JE and Hardisty JF. Fundamental and Applied Toxicology, 3: 315-319, 1983.



**JERRY F. HARDISTY, DVM, DACVP****PUBLICATIONS AND PAPERS – Continued**

Quality assurance in pathology for rodent carcinogenicity tests, by GA Boorman, CA Montgomery, JF Hardisty, SL Eustis, MJ Wolfe and EE McConnell. In: Handbook of Carcinogen Testing, (H Milman and E Weisberger, eds), pp. 345-357. New Jersey: Noyes Publications, 1985.

Systemic effects following inhalation of fog oil obscurant. Hardisty JF, Stead AG, Grose EC and Selgrade MJ. Presented at the North Carolina Chapter of the Society of Toxicology Meeting on February 2, 1985.

Factors influencing laboratory animal spontaneous tumor profiles. Hardisty JF. Toxicologic Pathology, 13, 91-104, 1985.

Pulmonary and hepatic health effects of inhalation of petroleum smoke. Grose EC, Stevenis MA, Illing JW, Jaskot RH, Hardisty JF and Stead A. The Toxicologist, Vol 6, No. 1, March 1986.

National Toxicology Program Pathology Quality Assurance Procedures, by J.F. Hardisty and GA Boorman. In: Managing Conduct and Data Quality of Toxicology Studies, (BK Hoover, JK Baldwin and AF Uelner. NIEHS/NTP – CE Whitmire, CL Davies and DW Bristol, eds), pp 263-269. New Jersey: Princeton Scientific Publishing Co. Inc., 1986.

Pulmonary Effects Due to Short Term Exposure to Oil Fog. Selgrade MJK, Hatch GE, Grose EC, Illing JW, Stead AG, Miller FJ, Graham JA, Stevens MA and Hardisty JF. Journal of Toxicological Environmental Health. 1987 21(1-2):173-85.

Arsine: Toxicity data from acute and subchronic inhalation exposures. MP Moorman, CR Moorman, JF Hardisty, SL Eustis, RE Morrissey, HR Sanders and BA Fowler. The Toxicologist, Vol 7, No. 1, February 1987.

Chronic toxicity and oncogenicity study of 2,6 diethylaniline. TG Pullin, RW Naismith, JF Hardisty, EB Whorton Jr. and GL Ter Haar. The Toxicologist, Vol 8, No. 1, February 1988.

Peripheral nerve sheath tumors, rat, by D.M. Walker, V.E. Walker, J.F. Hardisty, KT Morgan and JA Swenberg. In: ILSI Monographs on Pathology laboratory animals, nervous system, Vol 6, (TC Jones, U Mohr and RD Hunt, eds), New York, Springer-Verlag, 1988.

Pulmonary Effects Due to Subchronic Exposure to Oil Fog. Selgrade MK, Hatch GE, Grose EC, Stead AG, Miller FJ, Graham JA, Stevens MA, Hardisty JF. Toxicology and Industrial Health, Vol 6, No. 1, 1990 Jan, 6(1):123-43.

Thyroid gland, by JF Hardisty and GA Boorman. In: Pathology of the F344 Rat, (G Boorman, S Eustis, C Montgomery, M Elwell and W MacKenzie, eds), San Diego, Academic Press, 1990.

Oral cavity (pharynx, tongue, gingival teeth), esophagus and stomach, by HR Brown, JF Hardisty and SL Eustis. In: Pathology of the F344 Rat, (G Boorman, S Eustis, C Montgomery, M Elwell and W MacKenzie, eds), San Diego, Academic Press, 1990.

Toxicological pathology: a critical stage in study interpretation, by JF Hardisty and SL Eustis. In: Progress in Toxicology, (D Clayson, I Munro, P Shubik and J Swenberg, eds), Amsterdam, Elsevier, 1990.



**JERRY F. HARDISTY, DVM, DACVP**

**PUBLICATIONS AND PAPERS – Continued**

Tumors of the skin in the HRA/Skh mouse after treatment with 8-methoxypsoralen and UVA radiation. JK Dunnick, PD Forbes, SL Eustis and JF Hardisty. Fund. & Appl. Tox., Vol 16, 92-102, 1991.

Proliferative lesions of the mouse lung: Progression studies in Strain A mice. JF Foley, MW Anderson, GD Stoner, BW Gaul, JF Hardisty and RR Maronpot. Experimental Lung Research, Vol.17, 157-168, 1991.

Lesions of the rodent liver. Hardisty JF. Presented at the Dose Response Relationships for Hepatocarcinogenesis in Medaka Exposed to Waterborne N-Nitrosodiethylamine. Workshop on December 15, 1993.

Procedures for peer review in toxicologic pathology. Hardisty JF. Presented at The Society of Toxicologic Pathologist 13<sup>th</sup> International Symposium on June 5-9, 1994.

Necropsy and histology in toxicologic pathology. Hardisty JF. Presented at Industrial Toxicologic Pathology, University of Illinois at Urbana-Champaign, July 27, 1994.

A comparison of liver tumor diagnoses from seven PCB studies in rats. Moore John A, Hardisty Jerry F, Banas Deborah A and Smith, Mary Alice. Regulatory Toxicology and Pharmacology, Vol 20, 362-370, 1994.

Neoplastic lesions of questionable significance. Hardisty JF. Presented at the 1994 Toxicology Roundtable on October 3, 1994.

Use of nasal diagrams to record nasal lesions. Hardisty JF. Presented at the 1994 Toxicology Roundtable on October 4, 1994.

Morphologic assessment of pathologic changes in the rat larynx. Hardisty JF. Presented at the 1994 Toxicology Roundtable on October 4, 1994.

Pathology peer review and PWG. Hardisty JF. Presented at the 1995 Toxicology Roundtable in Nashville, TN on October 23, 1995

Peer review in toxicology pathology. Ward JM, Hardisty JF, Hailey JR and Street CS. Toxicologic Pathology ISSN:0192-6233, Vol. 23, No. 2, 1995

Computerized pathology data – summary vs. individual. Hardisty JF. Presented at the 1995 Toxicology Roundtable in Nashville, TN on October 24, 1995.

An evaluation of changes in the olfactory epithelium and liver peroxisome proliferation in mice after inhalation exposure to methylethylketoxime. Newton PE, Bolte HF, Lake

BG, Derelanko M, Rinehart WE and Hardisty JF. The Toxicologist, Vol 30, No. 1, Part 2, March 1996.

Peer review of histopathology data. Hardisty JF. Presented at the American College of Toxicology 17th Annual Meeting in King of Prussia, PA on November 11, 1996.

Pathology peer review in assessing carcinogenicity studies. Hardisty JF. Presented at the American College of Veterinary Pathologists' Thirty- First Annual Meeting in Seattle, Washington on December 5, 1996.



**JERRY F. HARDISTY, DVM, DACVP**

**PUBLICATIONS AND PAPERS – Continued**

Value of the mouse carcinogenicity bioassay (Summary). Hardisty JF. Toxicologic Pathology ISSN:0192-6233, Vol. 24, No. 6, 1996, pp. 720-721.

Interaction of consultants, contract laboratories and industry-Panel Discussion with HE Black, AM Dahlem, JF Hardisty, TG Terrell. Presented at Industrial Toxicologic Pathology, University of Illinois at Urbana-Champaign, May 19, 1997.

Controversial issues in anatomic pathology. JF Hardisty. Presented at Industrial Toxicologic Pathology, University of Illinois at Urbana-Champaign, May 20, 1997.

Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+) mice. Dunnick JK, Hardisty JF, Herbert RA, Seely JC, Furedi-Machacek EM, Foley JF, Lacks GD, Stasiewicz S and French JE. Toxicologic Pathology, Vol. 25, No. 6., 533-540, 1997.

Diagnostic dilemmas in toxicologic pathology. Hardisty Jerry. Presented at The 22nd Annual CL Davis DVM Foundation Continuing Education Symposium at North Carolina State University, College of Veterinary Medicine in Raleigh, North Carolina on June 14-18, 1998.

Thyroid and parathyroid glands, by JF Hardisty and GA Boorman. In: Pathology of the Mouse, (RR Maronpot, GA Boorman and BW Gaul, eds), Vienna, IL, Cache River Press, 1999.

Rodent Leydig Cell Tumorigenesis: A Review of the Physiology, Pathology, Mechanisms, and Relevance to Humans. Jon C Cook, Gary R Klinefelter, Jerry F Hardisty, Richard M Sharpe and Paul MD Foster. Critical Reviews in Toxicology 1999 March;29/169-261.

The nomenclature of cell death: recommendations of an ad hoc committee of Society of Toxicologic Pathologists. Levin S, Bucci TJ, Cohen SM, Fix AS, Hardisty JF, Legrand EK, Maronpot RR and Trump BF. Toxicologic Pathology. 1999 Jul-Aug;27(4):484-490.

Controversial issues in anatomic pathology. Hardisty Jerry. Presented as a course entitled *Industrial Toxicology and Pathology* for the American Registry of Pathology at the Ramada Inn in Bethesda, MD on September 28, 1999.

Histopathology of nasal olfactory mucosa from selected inhalation toxicity studies conducted with volatile chemicals. Hardisty JF, Garman RH, Harkema JR, Lomax LG and Morgan KT. Toxicologic Pathology, Vol.27, No. 6, pp. 618-627, 1999.

Pathology Working Groups: Current Concepts. Hardisty JF. Presented at the 16<sup>th</sup> Annual Meeting of the Society of Quality Assurance in Montreal, Canada on October 9-13, 2000.

Blind Pathology – When and When Not. Hardisty JF. Presented at the 51<sup>st</sup> Annual Toxicology Roundtable Program in Asheville, NC on October 15-18, 2000.

Short-Term, Subchronic, and Chronic Toxicology Studies, by NH Wilson, JF Hardisty and JR Hayes. In: Principles and Methods of Toxicology, 4<sup>th</sup> Edition, (Wallace Hayes, ed), ISBN 1-56032-814-2, 2000.

Methods to identify and characterize developmental neurotoxicity for human health risk assessment. II: neuropathology. Garman RH, Fix AS, Jortner BS, Hardisty JF, Claudio L and Ferenc S. Environmental Health Perspectives, Vol. 109, pp. 93-100, March 2001.



**JERRY F. HARDISTY, DVM, DACVP**

**PUBLICATIONS AND PAPERS – Continued**

A chronic inhalation toxicity/oncogenicity study of methylethylketoxime in rats and mice. Newton PE, Wooding WL, Bolte HF, Derelanko MJ, Hardisty JF and Rinehart WE. *Inhalation Toxicology*, 13:1093-1116, 2001.

Carcinogenic assessment of premarloxacin in rats and mice. White KA, Daniel EM, Botta JA, Clare LJ, Barnett D, Hildebrandt P, Hardisty JF and Lucas MJ. Presented as a poster for the Society of Toxicologic Pathology and the International Federation of Societies of Toxicologic Pathologists in Orlando, Florida on June 24-28, 2001.

The Pathologist and Pathology Data. Hardisty JF. Presented at FDA CEDR on May 31, 2001.

Inhalation Toxicology of Octamethylcyclotetrasiloxane (D4) Following a 3-month Nose-Only Exposure in Fischer 344 rats. Burns-Naas LA, Meeks RG, Kolesar GB, Mast RW, Elwell MR, Hardisty JF, Thevenaz P. *International Journal of Toxicology* 2002 Jan-Feb;21(1):39-53.

Quality review procedures necessary for rodent pathology databases and toxicogenomic studies: The National Toxicology Program Experience. Boorman GA, Haseman JK, Waters WD, Hardisty JF and Sills RC. *Toxicologic Pathology*. 30, 88-92, 2002.

Inhalation toxicology of octamethylcyclotetrasiloxane (D<sub>4</sub>) following a 3-month nose-only exposure in Fischer 344 rats. Burns-Naas LA, Meeks RG, Kolesar GB, Mast RW, Elwell MR, Hardisty JF and Thevenaz P. *International Journal of Toxicology*, ISSN 1091-5818, Vol. 21, No. 1, pp 39-53, 2002.

Diagnostic dilemmas in toxicologic pathology. Presented at the 5<sup>th</sup> Industrial Toxicology and Pathology Course and symposium in Chicago, IL on July 9, 2002.

Histologic artifacts & diagnostic dilemmas. Presented at the RTP Rodent Pathology Course, Research Triangle Park, NC on September 8-10, 2002.

Comparative prevalence, multiplicity, and progression of spontaneous and vinyl carbamate-induced liver lesions in five strains of male mice. Takahashi K, Dinse GE, Foley JF and Maronpot RR. *Toxicologic Pathology*, Vol 30, No. 5, pp 599-605, 2002.

Propylene glycol monomethyl ether (PGME): inhalation toxicity and carcinogenicity in Fischer 344 rats and B6C3F1 mice. *Toxicologic Pathology*, Vol 30, No. 5, pp 570-579, 2002.

An evaluation of changes and recovery in the olfactory epithelium in mice after inhalation exposure to methylethylketoxime. Newton PE, Bolte HF, Derelanko MJ, Hardisty JF and Rinehart WE. *Inhalation Toxicology*, 14:1249-1260, 2002.

The pathologist and pathology data. Hardisty JF. Presented at NIEHS, RTP, NC on February 29, 2002.

The pathologist and pathology data. Hardisty JF. Presented at the SOT Meeting in Nashville, TN on March 2002.

Propylene Glycol Monomethyl Ether (PGME); Inhalation Toxicity and Carcinogenicity in Fischer 344 rats and B6C3F1 mice. Spencer PJ, Crissman JW, Stott WT, Corley RA, Cieszlak FS, Schumann AM, Hardisty JF. *Toxicological Pathology* 2002 Sep-Oct;30(5):570-9.

Histologic artifacts and diagnostic dilemmas. Hardisty JF. Presented at NCTR in Jefferson, AR on October 31, 2002.